- Home
- Software Solutions
- Resources
- Corporate
News feeds from around the industry (Updated Hourly) - Updated on August 01, 2010
BioSpace
>Hard To Treat Diseases Incorporated Seeks Sale of Slavica Biochem to US-based Biomedical Firm SHENZHEN, CHINA--(Marketwire - 07/29/10) - Hard to Treat Diseases, Inc. (Pinksheets:HTDS - News)(http://www.htdsmedical.com) announces the company's intention to sell current subsidiary Slavica Biochem to a US-based publicly traded biomedical company.HTDS is pleased with the performance of Slavica, a Belgrade-based medical research centre that is currently evaluating various medications and...
>Orexigen Therapeutics, Inc. Obesity Pill Shows Promise in Phase III Study; Stock Rises 9.47% at 1:20PM EDT SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration...
>Hard To Treat Diseases Incorporated Seeks Sale of to US-based Biomedical Firm SHENZHEN, CHINA--(Marketwire - 07/29/10) - Hard to Treat Diseases, Inc. (Pinksheets:HTDS - News)(http://www.htdsmedical.com) announces the company's intention to sell current subsidiary Slavica Biochem to a US-based publicly traded biomedical company.HTDS is pleased with the performance of Slavica, a Belgrade-based medical research centre that is currently evaluating various medications and...
>Anacor Pharmaceuticals, Inc. to Receive $15 Million Payment from GlaxoSmithKline Business Week -- Anacor Pharmaceuticals said Thursday it will receive a $15 million payment from GlaxoSmithKline on a deal over a potential antibiotic.
>Dense Bones Linked To Raised Risk For Prostate Cancer, National Institute on Aging and Johns Hopkins University School of Medicine Study New Kerala -- Washington, July 29 : A new study has found that men, who develop prostate cancer, tend to retain denser bones as they age than men who stay free of the disease.
>Hard To Treat Diseases Incorporated Seeks Sale of Slavica Biochem to US-based Biomedical Firm SHENZHEN, CHINA--(Marketwire - 07/29/10) - Hard to Treat Diseases, Inc. (Pinksheets:HTDS - News)(http://www.htdsmedical.com) announces the company's intention to sell current subsidiary Slavica Biochem to a US-based publicly traded biomedical company.HTDS is pleased with the performance of Slavica, a Belgrade-based medical research centre that is currently evaluating various medications and...
>Orexigen Therapeutics, Inc. Obesity Pill Shows Promise in Phase III Study; Stock Rises 9.47% at 1:20PM EDT SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration...
>Hard To Treat Diseases Incorporated Seeks Sale of to US-based Biomedical Firm SHENZHEN, CHINA--(Marketwire - 07/29/10) - Hard to Treat Diseases, Inc. (Pinksheets:HTDS - News)(http://www.htdsmedical.com) announces the company's intention to sell current subsidiary Slavica Biochem to a US-based publicly traded biomedical company.HTDS is pleased with the performance of Slavica, a Belgrade-based medical research centre that is currently evaluating various medications and...
>Anacor Pharmaceuticals, Inc. to Receive $15 Million Payment from GlaxoSmithKline Business Week -- Anacor Pharmaceuticals said Thursday it will receive a $15 million payment from GlaxoSmithKline on a deal over a potential antibiotic.
>Dense Bones Linked To Raised Risk For Prostate Cancer, National Institute on Aging and Johns Hopkins University School of Medicine Study New Kerala -- Washington, July 29 : A new study has found that men, who develop prostate cancer, tend to retain denser bones as they age than men who stay free of the disease.
BioSpace - Breaking News
>Siegfried Outsources Support Functions Zofingen, July 30, 2010 -- Siegfried Holding AG (SIX: SFZN) signed a cooperation agreement with two companies concerning the supply of support functions. In the future, Bilfinger Berger Industrial Ser-vices Swiss AG will provide maintenance, part of the engineering and security services and run the Siegfried HAZMAT Training Center. All issues concerning utility supply and waste disposal will...
>Stellar Pharmaceuticals Inc. Signs Agreement With Laboratorios Inibsa, S.A. for Distribution and Sale of Uracyst(R) in Spain LONDON, ONTARIO--(Marketwire - July 30, 2010) - Stellar Pharmaceuticals Inc. ("Stellar") (OTCBB: SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported signing an license agreement with Laboratorios Inibsa, S.A...
>WuXi AppTec, Inc.??'s CEO Blames Short-Term Financial Concerns for Merger's Demise July 30, 2010 -- In an open letter to interested parties, Dr. Ge Li, Chairman and CEO of WuXi AppTec, said short-term financial concerns were the reason its merger with Charles River Labs was not completed. Dr. Li expressed regret that the failure of the merger would slow WuXis evolution into a company with a broader set of CRO capabilities. More details...
>Curaxis Pharmaceutical Corp. Announces Completion of Reverse Merger With DURHAM, N.C., July 29, 2010 (GLOBE NEWSWIRE) -- Curaxis Pharmaceutical Corp. ("Curaxis") is pleased to announce the completion of its reverse merger (the "Merger") with Auto Search Cars, Inc. ("Auto Search") (OTCBB:ASCH). The effective date of the Merger is July 29, 2010.
>Ruling May Force Cody Laboratories, Inc. To Halt Making Morphine; May Have To Lay Off Some 50 Workers Billings Gazette -- CODY A federal judge has denied a last-minute request by Wyomings only pharmaceutical manufacturer to block a pending enforcement action that appears likely to force the company to cease manufacturing a potent painkiller.
>Siegfried Outsources Support Functions Zofingen, July 30, 2010 -- Siegfried Holding AG (SIX: SFZN) signed a cooperation agreement with two companies concerning the supply of support functions. In the future, Bilfinger Berger Industrial Ser-vices Swiss AG will provide maintenance, part of the engineering and security services and run the Siegfried HAZMAT Training Center. All issues concerning utility supply and waste disposal will...
>Stellar Pharmaceuticals Inc. Signs Agreement With Laboratorios Inibsa, S.A. for Distribution and Sale of Uracyst(R) in Spain LONDON, ONTARIO--(Marketwire - July 30, 2010) - Stellar Pharmaceuticals Inc. ("Stellar") (OTCBB: SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported signing an license agreement with Laboratorios Inibsa, S.A...
>WuXi AppTec, Inc.??'s CEO Blames Short-Term Financial Concerns for Merger's Demise July 30, 2010 -- In an open letter to interested parties, Dr. Ge Li, Chairman and CEO of WuXi AppTec, said short-term financial concerns were the reason its merger with Charles River Labs was not completed. Dr. Li expressed regret that the failure of the merger would slow WuXis evolution into a company with a broader set of CRO capabilities. More details...
>Curaxis Pharmaceutical Corp. Announces Completion of Reverse Merger With DURHAM, N.C., July 29, 2010 (GLOBE NEWSWIRE) -- Curaxis Pharmaceutical Corp. ("Curaxis") is pleased to announce the completion of its reverse merger (the "Merger") with Auto Search Cars, Inc. ("Auto Search") (OTCBB:ASCH). The effective date of the Merger is July 29, 2010.
>Ruling May Force Cody Laboratories, Inc. To Halt Making Morphine; May Have To Lay Off Some 50 Workers Billings Gazette -- CODY A federal judge has denied a last-minute request by Wyomings only pharmaceutical manufacturer to block a pending enforcement action that appears likely to force the company to cease manufacturing a potent painkiller.
Biotech News - Business Wire
>Complete Genomics, Inc. Files Registration Statement for Proposed Initial Public OfferingMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Complete Genomics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (?SEC?) relating to the proposed initial public offering of shares of its common stock. The shares of common stock to be sold in this offering are proposed to be sold solely by Complete Genomics, Inc. UBS Investment Bank and Jefferies & Company will be acting as joint book-running managers, with Baird and Cowen ...
>Company Profile for IMIX Americas, Inc.--(BUSINESS WIRE)--IMIX manufactures, integrates, tests, markets and services complete digital radiography (DR) systems, including digital detectors and positioning devices, for a wide variety of clinical settings.
>ZIOPHARM Reports Second Quarter Financial Results and Updates Clinical ProgramsNEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical cancer company addressing unmet medical needs, today reported its financial results for the three months ended June 30, 2010 and provided an update on the Company?s continued progress with its clinical programs. For the second quarter of 2010, the Company?s cash used in operations was $4.3 million, an increase of $2.1 million from $2.2 million for the same period for 2009. The spending increase is attributa...
>ZOLL Medical Corporation to Speak at the Wedbush Securities Life Sciences Best Ideas MAC ConferenceCHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that Richard A. Packer, its Chief Executive Officer and Jonathan Rennert, its President, will speak at 10:00 a.m. on Tuesday, August 3, 2010 in New York City, at the Wedbush Securities Life Sciences Best Ideas MAC Conference being held at the Le Parker Meridien Hotel, 118 West 57th Street, New York, NY 10019. They will discuss ZOLL?s bu...
>Geron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based TherapyMENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron?s Investigational New Drug (IND) application has been lifted and the company?s Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed. The FDA notification enables Geron to move forward with the world?s first clinical trial of a human embryonic stem cell (hESC)-base...
>Complete Genomics, Inc. Files Registration Statement for Proposed Initial Public OfferingMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Complete Genomics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (?SEC?) relating to the proposed initial public offering of shares of its common stock. The shares of common stock to be sold in this offering are proposed to be sold solely by Complete Genomics, Inc. UBS Investment Bank and Jefferies & Company will be acting as joint book-running managers, with Baird and Cowen ...
>Company Profile for IMIX Americas, Inc.--(BUSINESS WIRE)--IMIX manufactures, integrates, tests, markets and services complete digital radiography (DR) systems, including digital detectors and positioning devices, for a wide variety of clinical settings.
>ZIOPHARM Reports Second Quarter Financial Results and Updates Clinical ProgramsNEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical cancer company addressing unmet medical needs, today reported its financial results for the three months ended June 30, 2010 and provided an update on the Company?s continued progress with its clinical programs. For the second quarter of 2010, the Company?s cash used in operations was $4.3 million, an increase of $2.1 million from $2.2 million for the same period for 2009. The spending increase is attributa...
>ZOLL Medical Corporation to Speak at the Wedbush Securities Life Sciences Best Ideas MAC ConferenceCHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that Richard A. Packer, its Chief Executive Officer and Jonathan Rennert, its President, will speak at 10:00 a.m. on Tuesday, August 3, 2010 in New York City, at the Wedbush Securities Life Sciences Best Ideas MAC Conference being held at the Le Parker Meridien Hotel, 118 West 57th Street, New York, NY 10019. They will discuss ZOLL?s bu...
>Geron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based TherapyMENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron?s Investigational New Drug (IND) application has been lifted and the company?s Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed. The FDA notification enables Geron to move forward with the world?s first clinical trial of a human embryonic stem cell (hESC)-base...
Biotech News - PR Newswire
>PharmAthene Provides Update on NYSE Amex Listing Compliance PlanANNAPOLIS, Md., July 30 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that on July 26, 2010 it received a letter from the NYSE Amex LLC, stating that PharmAthene is not in
>Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare ConferenceSAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010 at 1:15 p.m. EDT (10:15 a.m. PDT). The conference is being held at the
>European Union Approves Maize with Herculex® I/Herculex® RW and Herculex® RW/ Herculex® I/Roundup Ready® Corn 2 Trait Stacks for Import, Food, Feed & ProcessingBRUSSELS, July 30 /PRNewswire-FirstCall/ -- The European Commission announced that it has granted import, food, feed and processing approvals for biotechnology maize products jointly developed by DuPont (NYSE: DD) business Pioneer Hi-Bred and Dow AgroSciences LLC, a wholly owned subsidiary of
>WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call SHANGHAI, July 30 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of
>Conatus Pharmaceuticals Acquires Pfizer's Idun SubsidiarySAN DIEGO, July 30 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc. Financial terms were not disclosed. Conatus Pharmaceuticals is a privately-held drug development company focused on liver disease and o
>PharmAthene Provides Update on NYSE Amex Listing Compliance PlanANNAPOLIS, Md., July 30 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that on July 26, 2010 it received a letter from the NYSE Amex LLC, stating that PharmAthene is not in
>Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare ConferenceSAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010 at 1:15 p.m. EDT (10:15 a.m. PDT). The conference is being held at the
>European Union Approves Maize with Herculex® I/Herculex® RW and Herculex® RW/ Herculex® I/Roundup Ready® Corn 2 Trait Stacks for Import, Food, Feed & ProcessingBRUSSELS, July 30 /PRNewswire-FirstCall/ -- The European Commission announced that it has granted import, food, feed and processing approvals for biotechnology maize products jointly developed by DuPont (NYSE: DD) business Pioneer Hi-Bred and Dow AgroSciences LLC, a wholly owned subsidiary of
>WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call SHANGHAI, July 30 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of
>Conatus Pharmaceuticals Acquires Pfizer's Idun SubsidiarySAN DIEGO, July 30 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc. Financial terms were not disclosed. Conatus Pharmaceuticals is a privately-held drug development company focused on liver disease and o
Biotechnology - Moreover
>Synthesis and Antiproliferative Evaluation of Certain Indeno[1,2-c]quinoline Derivatives. Part 2Institute of Clinical Medicine, National Cheng-Kung University, School of Medicine, 138 Sheng-Li Road, Tainan 704, Taiwan? Institute of Biotechnology, National University of Kaohsiung, 700 Kaohsiung University Road, Kaohsiung, Taiwan
>PPD, Inc. (PPDI) Expands cGMP Laboratory Services in North AmericacGMP laboratory testing services into Wayne, Pa., to meet growing client demand for these services from pharmaceutical and biotechnology companies located in the northeastern United States
>The Dynamic Media, Sera and Reagent Market in BiotechnologyTotal worldwide sales revenues for media, sera, and reagent used in the biotechnology were $2,546.2million in 2010, and are expected to increase to more than $3800 Million in 2015, at a compound annual growth rate (CAGR) of 8.7%. The largest
>Sanofi interest drives up Genzyme sharesFrench drug maker Sanofi-Aventis SA?s efforts to buy Genzyme Corp. have driven up shares of the Cambridge-based biotechnology company. Sanofi chief executive Chris Viehbacher has support from his board of directors to offer as much as $70 a share for
>Govt to set up regulatory authority for Biotech & GMBangalore, Jul 31 The government is in the process of setting up a regulatory authority for biotechnology and genetic modification, Planning Commission Deputy Chairman Montek Singh Ahluwalia said today
>Synthesis and Antiproliferative Evaluation of Certain Indeno[1,2-c]quinoline Derivatives. Part 2Institute of Clinical Medicine, National Cheng-Kung University, School of Medicine, 138 Sheng-Li Road, Tainan 704, Taiwan? Institute of Biotechnology, National University of Kaohsiung, 700 Kaohsiung University Road, Kaohsiung, Taiwan
>PPD, Inc. (PPDI) Expands cGMP Laboratory Services in North AmericacGMP laboratory testing services into Wayne, Pa., to meet growing client demand for these services from pharmaceutical and biotechnology companies located in the northeastern United States
>The Dynamic Media, Sera and Reagent Market in BiotechnologyTotal worldwide sales revenues for media, sera, and reagent used in the biotechnology were $2,546.2million in 2010, and are expected to increase to more than $3800 Million in 2015, at a compound annual growth rate (CAGR) of 8.7%. The largest
>Sanofi interest drives up Genzyme sharesFrench drug maker Sanofi-Aventis SA?s efforts to buy Genzyme Corp. have driven up shares of the Cambridge-based biotechnology company. Sanofi chief executive Chris Viehbacher has support from his board of directors to offer as much as $70 a share for
>Govt to set up regulatory authority for Biotech & GMBangalore, Jul 31 The government is in the process of setting up a regulatory authority for biotechnology and genetic modification, Planning Commission Deputy Chairman Montek Singh Ahluwalia said today
Burrill Report
>An Urging for Emerging
>The Deals That Didn?t Get Done
>NEJM Editorial Raises Questions About Dendreon's Cancer Vaccine Study
>IPO Market Sizzles - In China Wondering if the IPO window is open? Well there’s no doubt about it if you are talking about the IPO market in China. The life sciences sector has raised $6.1 billion through initial public offerings in the past 12 months, far outpacing the activity in the United States. We spoke to Greg Scott, president and founder of the consulting firm ChinaBio and publisher of ChinaBio Today about the thriving IPO market for life sciences companies there, how that’s evolved over the past yea...
>Charles River Calls off WuXi Deal Charles River Laboratories and WuXi PharmaTech terminated their acquisition agreement due to investor opposition by Jana Partners, Charles River’s largest shareholder. The contract research organization giant will pay WuXi a $30 million breakup fee as a result.
>An Urging for Emerging
>The Deals That Didn?t Get Done
>NEJM Editorial Raises Questions About Dendreon's Cancer Vaccine Study
>IPO Market Sizzles - In China Wondering if the IPO window is open? Well there’s no doubt about it if you are talking about the IPO market in China. The life sciences sector has raised $6.1 billion through initial public offerings in the past 12 months, far outpacing the activity in the United States. We spoke to Greg Scott, president and founder of the consulting firm ChinaBio and publisher of ChinaBio Today about the thriving IPO market for life sciences companies there, how that’s evolved over the past yea...
>Charles River Calls off WuXi Deal Charles River Laboratories and WuXi PharmaTech terminated their acquisition agreement due to investor opposition by Jana Partners, Charles River’s largest shareholder. The contract research organization giant will pay WuXi a $30 million breakup fee as a result.
CenterWatch - Clinical Trials
>QPS completes acquisition of XendoQPS Holdings, a CRO providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development (XDD), headquartered in Groningen, The Netherlands. XDD, a European CRO, will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC. XDD has large and small molecule bioanalytical laboratories and a dedicated 24-bed clinical pharmacology unit (CPU) located at University Medical Cent...
>Bostwick in partnership with American International Biotechnology Bostwick Scientific, the clinical trials division of Bostwick Laboratories, a global central anatomic pathology laboratory, announced a partnership with American International Biotechnology Services(AIBioTech.) Together, these two organizations offer capabilities in anatomic pathology and molecular biology, microbiology, virology and protein chemistry services for the biopharmaceutical industry. These services are offered individually or can be integrated to support product development from ...
>PharmaNet in collaboration with Abacus InternationalPharmaNet Development Group, a global contract research organization (CRO) announced a strategic collaboration with Abacus International, one of the largest independent health economic consultancies in Europe. The strategic collaboration builds on the organizations? common purpose of supporting the development of research-based evidence throughout the drug/device lifecycle to document a product?s clinical and economic value. ...
>BIO Ventures for Global Health expands to West Coast Washington, D.C.-based BIO Ventures for Global Health (BVGH) is expanding to the West Coast with the opening of a new San Francisco headquarters. The expansion provides BVGH the opportunity to work closely with biotech and investor communities on both coasts. Jacqueline Papkoff, PhD was appointed vice president of Global Health Connect, a new network created to link biopharmaceutical companies with product development partnerships, academics, NGOs, developing country re...
>ACRO hails proposed privacy rule to help simplify clinical researchThe Association of Clinical Research Organizations (ACRO) has commended the long-awaited privacy rule issued by the Department of Health and Human Services (HHS), saying the proposal strikes an ?appropriate balance? between protecting patients and allowing researchers access to health information critical for drug safety monitoring and comparative effectiveness studies. ACRO raised concerns with various governmental agencies about a provision in last year?s Health Information Technology for E...
>QPS completes acquisition of XendoQPS Holdings, a CRO providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development (XDD), headquartered in Groningen, The Netherlands. XDD, a European CRO, will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC. XDD has large and small molecule bioanalytical laboratories and a dedicated 24-bed clinical pharmacology unit (CPU) located at University Medical Cent...
>Bostwick in partnership with American International Biotechnology Bostwick Scientific, the clinical trials division of Bostwick Laboratories, a global central anatomic pathology laboratory, announced a partnership with American International Biotechnology Services(AIBioTech.) Together, these two organizations offer capabilities in anatomic pathology and molecular biology, microbiology, virology and protein chemistry services for the biopharmaceutical industry. These services are offered individually or can be integrated to support product development from ...
>PharmaNet in collaboration with Abacus InternationalPharmaNet Development Group, a global contract research organization (CRO) announced a strategic collaboration with Abacus International, one of the largest independent health economic consultancies in Europe. The strategic collaboration builds on the organizations? common purpose of supporting the development of research-based evidence throughout the drug/device lifecycle to document a product?s clinical and economic value. ...
>BIO Ventures for Global Health expands to West Coast Washington, D.C.-based BIO Ventures for Global Health (BVGH) is expanding to the West Coast with the opening of a new San Francisco headquarters. The expansion provides BVGH the opportunity to work closely with biotech and investor communities on both coasts. Jacqueline Papkoff, PhD was appointed vice president of Global Health Connect, a new network created to link biopharmaceutical companies with product development partnerships, academics, NGOs, developing country re...
>ACRO hails proposed privacy rule to help simplify clinical researchThe Association of Clinical Research Organizations (ACRO) has commended the long-awaited privacy rule issued by the Department of Health and Human Services (HHS), saying the proposal strikes an ?appropriate balance? between protecting patients and allowing researchers access to health information critical for drug safety monitoring and comparative effectiveness studies. ACRO raised concerns with various governmental agencies about a provision in last year?s Health Information Technology for E...
Clinical Trials - Business Wire
>Medtronic Launches Novel Clinical Trial Evaluating Spinal Cord Stimulation Therapy for Heart FailureMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the global launch of the Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial. It is the industry?s first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation (SCS), or neurostimulation, to improve clinical signs and symptoms of heart failure. More than 5 million Americans and 22 million people worldwide h...
>Ortho Kinematics Launches Multi-Site Clinical Study of KineGraph VMA?AUSTIN, Texas--(BUSINESS WIRE)--Ortho Kinematics, a privately held spine diagnostics company focused on revolutionizing spine motion analysis, announced today that it has begun a multi-site clinical study of the KineGraph VMA?, and that the initial 23 patients have been enrolled. The study will help determine which types of patients are best evaluated with KineGraph VMA testing. The KineGraph VMA is designed to provide functional diagnostic information to spine surgeons to be used in conjunct...
>Exact Sciences? Methylation Detection Technology Achieves 100 Percent Sensitivity, SpecificityANAHEIM, Calif.--(BUSINESS WIRE)--Data being presented by Exact Sciences at the American Association of Clinical Chemistry meeting demonstrates that its methylation specific technology found 100% of colorectal cancers and precancers.
>iMedicor Launches Phase I Product Marketing Program for MuGardNANUET, N.Y.--(BUSINESS WIRE)--The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion worldwide.
>Research and Markets: Patient and Investigator Recruitment Success - Now AvailableDUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/610cbc/patient_and_invest) has announced the addition of the "Patient and Investigator Recruitment Success" report to their offering. Consistent with ISR's mission, this study tackles significant industry issues with rigor and insight. It is a landmark study based on interviews with 362 patients, principal investigators and drug development professionals. Respondents discuss in detail the drivers and bar...
>Medtronic Launches Novel Clinical Trial Evaluating Spinal Cord Stimulation Therapy for Heart FailureMINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the global launch of the Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial. It is the industry?s first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation (SCS), or neurostimulation, to improve clinical signs and symptoms of heart failure. More than 5 million Americans and 22 million people worldwide h...
>Ortho Kinematics Launches Multi-Site Clinical Study of KineGraph VMA?AUSTIN, Texas--(BUSINESS WIRE)--Ortho Kinematics, a privately held spine diagnostics company focused on revolutionizing spine motion analysis, announced today that it has begun a multi-site clinical study of the KineGraph VMA?, and that the initial 23 patients have been enrolled. The study will help determine which types of patients are best evaluated with KineGraph VMA testing. The KineGraph VMA is designed to provide functional diagnostic information to spine surgeons to be used in conjunct...
>Exact Sciences? Methylation Detection Technology Achieves 100 Percent Sensitivity, SpecificityANAHEIM, Calif.--(BUSINESS WIRE)--Data being presented by Exact Sciences at the American Association of Clinical Chemistry meeting demonstrates that its methylation specific technology found 100% of colorectal cancers and precancers.
>iMedicor Launches Phase I Product Marketing Program for MuGardNANUET, N.Y.--(BUSINESS WIRE)--The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion worldwide.
>Research and Markets: Patient and Investigator Recruitment Success - Now AvailableDUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/610cbc/patient_and_invest) has announced the addition of the "Patient and Investigator Recruitment Success" report to their offering. Consistent with ISR's mission, this study tackles significant industry issues with rigor and insight. It is a landmark study based on interviews with 362 patients, principal investigators and drug development professionals. Respondents discuss in detail the drivers and bar...
Clinical Trials - PR Newswire
>Study Results Show That Oral Contraceptives/Hormone Replacement Therapy May Protect Against Brain AneurysmsFindings Announced at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting CARLSBAD, Calif., July 30 /PRNewswire-USNewswire/ -- Results from a retrospective, case-control study presented today at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting could have si
>NASA Talk is High Tech Prescription for Contact LensesHAMPTON, Va., July 30 /PRNewswire-USNewswire/ -- Imagine your contact lenses being able to improve your vision and tell your temperature. (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO) (Logo: http://photos.prnewswire.com/prnh/20081007/38461LOGO) On Tuesday, Aug. 3, at NASA's L
>Researchers Find New Translocation; Weak Spots in DNA Cause Genetic DiseasePHILADELPHIA, July 29 /PRNewswire-USNewswire/ --A genetics research team based at The Children's Hospital of Philadelphia continues to discover recurrent translocations—places in which two chromosomes exchange pieces of themselves. As many as 1 in 600 persons carry balanced chromosome transloc
>Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS)HAYWARD, Calif., July 29 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Ac
>New York State Approves Quest Diagnostics' Fragile X Syndrome TestMADISON, N.J., July 28 /PRNewswire/ -- An accurate, faster testing option to identify female carriers and other patients with genetic abnormalities that cause Fragile X Syndrome is now available to physicians in all fifty states with the recent approval in New York. Fragile X is the leading cause of
>Study Results Show That Oral Contraceptives/Hormone Replacement Therapy May Protect Against Brain AneurysmsFindings Announced at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting CARLSBAD, Calif., July 30 /PRNewswire-USNewswire/ -- Results from a retrospective, case-control study presented today at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting could have si
>NASA Talk is High Tech Prescription for Contact LensesHAMPTON, Va., July 30 /PRNewswire-USNewswire/ -- Imagine your contact lenses being able to improve your vision and tell your temperature. (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO) (Logo: http://photos.prnewswire.com/prnh/20081007/38461LOGO) On Tuesday, Aug. 3, at NASA's L
>Researchers Find New Translocation; Weak Spots in DNA Cause Genetic DiseasePHILADELPHIA, July 29 /PRNewswire-USNewswire/ --A genetics research team based at The Children's Hospital of Philadelphia continues to discover recurrent translocations—places in which two chromosomes exchange pieces of themselves. As many as 1 in 600 persons carry balanced chromosome transloc
>Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS)HAYWARD, Calif., July 29 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Ac
>New York State Approves Quest Diagnostics' Fragile X Syndrome TestMADISON, N.J., July 28 /PRNewswire/ -- An accurate, faster testing option to identify female carriers and other patients with genetic abnormalities that cause Fragile X Syndrome is now available to physicians in all fifty states with the recent approval in New York. Fragile X is the leading cause of
Contract Pharma
>Charles River, WuXi Terminate Acquisition Agreement Charles River Laboratories and WuXi PharmaTech, Inc. have decided to terminate their previously announced acquisition agreement. Under the termination agreement, Charles River will pay WuXi a $30 million breakup fee for full satisfaction of the parties’ obligations under the acquisition agreement. Charles River also announced that its board of directors has authorized a new $500 million stock repurchase program. James C. Foster, chairman, president and chief executive officer said, &...
>Financial Report: Merck 2QMerck 2Q 2Q Revenues: $11.3 billion (+92%) 2Q Earnings: $780.2 million (-51%) YTD Revenues: $22.8 billion (earnings were $11.3 billion YTD09) YTD Earnings: $1.1 billion (-64%) Comments: Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%). Zetia sales were $564 million (+1%) and Vytorin sales were $490 million (-8%). Isentress sales jumped 55% to $267 million. Cozaar/Hyzaar sales were down 46% to $485 million due to generic competiti...
>PPD Expands North America Lab Services PPD, Inc. has expanded its cGMP lab testing services into Wayne, PA to expand its services in the northeastern U.S. The 5,000-sq.-ft. facility will provide small and large molecule testing for a full range of product development programs including vaccines and biologics. The expansion is designed to allow the company to deliver more streamlined project management and easier logistics for companies working in vaccine or biologics development. “Expanding our cGMP laboratory operations ...
>Harmony Establishes Innovation DepartmentHarmony Labs has established a department focused on innovation and new product development. The new innovation team will work with the company’s R&D department to explore new concepts, product differentiation, and new technologies. Natalie Barger, senior manager of product development and innovation will lead the department’s efforts. “Innovation is a key pillar in our core strategy and this investment demonstrates Harmony Labs’ commitment to deliver not just new ...
>Financial Report: Covance 2QCovance 2Q 2Q Revenues: $500.7 million (+2%) 2Q Earnings: $31.7 million (-26%) YTD Revenues: $1.0 billion (+5%) YTD Earnings: $70.8 million (-15%) Comments: Late-Stage Development revenues in the quarter were flat at $267.0 million. Early Development revenues were $208.2 million (+4%). Backlog at June 30, 2010 grew 4% to $4.8 billion but was negatively impacted by Foreign exchange by $31 million.
>Charles River, WuXi Terminate Acquisition Agreement Charles River Laboratories and WuXi PharmaTech, Inc. have decided to terminate their previously announced acquisition agreement. Under the termination agreement, Charles River will pay WuXi a $30 million breakup fee for full satisfaction of the parties’ obligations under the acquisition agreement. Charles River also announced that its board of directors has authorized a new $500 million stock repurchase program. James C. Foster, chairman, president and chief executive officer said, &...
>Financial Report: Merck 2QMerck 2Q 2Q Revenues: $11.3 billion (+92%) 2Q Earnings: $780.2 million (-51%) YTD Revenues: $22.8 billion (earnings were $11.3 billion YTD09) YTD Earnings: $1.1 billion (-64%) Comments: Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%). Zetia sales were $564 million (+1%) and Vytorin sales were $490 million (-8%). Isentress sales jumped 55% to $267 million. Cozaar/Hyzaar sales were down 46% to $485 million due to generic competiti...
>PPD Expands North America Lab Services PPD, Inc. has expanded its cGMP lab testing services into Wayne, PA to expand its services in the northeastern U.S. The 5,000-sq.-ft. facility will provide small and large molecule testing for a full range of product development programs including vaccines and biologics. The expansion is designed to allow the company to deliver more streamlined project management and easier logistics for companies working in vaccine or biologics development. “Expanding our cGMP laboratory operations ...
>Harmony Establishes Innovation DepartmentHarmony Labs has established a department focused on innovation and new product development. The new innovation team will work with the company’s R&D department to explore new concepts, product differentiation, and new technologies. Natalie Barger, senior manager of product development and innovation will lead the department’s efforts. “Innovation is a key pillar in our core strategy and this investment demonstrates Harmony Labs’ commitment to deliver not just new ...
>Financial Report: Covance 2QCovance 2Q 2Q Revenues: $500.7 million (+2%) 2Q Earnings: $31.7 million (-26%) YTD Revenues: $1.0 billion (+5%) YTD Earnings: $70.8 million (-15%) Comments: Late-Stage Development revenues in the quarter were flat at $267.0 million. Early Development revenues were $208.2 million (+4%). Backlog at June 30, 2010 grew 4% to $4.8 billion but was negatively impacted by Foreign exchange by $31 million.
FDA Drugs- What's New
>FDA Drug Safety Communication: Ongoing safety review of Evamist (estradiol transdermal spray) and unintended exposure of children and pets to topical estrogen[07-29-2010] The U.S. Food and Drug Administration (FDA) is reviewing reports of adverse effects from Evamist in children who may have been unintentionally exposed to the drug through skin contact with women using this product.
>FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin)
>FDA Statement on Avandia TIDE Trial
>FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide)[07-13-2010] The U.S. Food and Drug Administration (FDA) is adding information on severe liver injury to the Boxed Warning of Arava (leflunomide) – a drug used to treat rheumatoid arthritis - to highlight the risk of severe liver injury in patients using this drug and how this risk may be reduced.
>FDA Drug Safety Communication: New risk management plan and patient Medication Guide for Qualaquin (quinine sulfate)[07-08-2010] Due to continued reports of serious side effects in patients using Qualaquin "off-label" (a non-FDA-approved use) for night time leg cramps, the U.S. Food and Drug Administration (FDA) has approved a risk management plan to warn against the use of this drug for such unapproved uses.
>FDA Drug Safety Communication: Ongoing safety review of Evamist (estradiol transdermal spray) and unintended exposure of children and pets to topical estrogen[07-29-2010] The U.S. Food and Drug Administration (FDA) is reviewing reports of adverse effects from Evamist in children who may have been unintentionally exposed to the drug through skin contact with women using this product.
>FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin)
>FDA Statement on Avandia TIDE Trial
>FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide)[07-13-2010] The U.S. Food and Drug Administration (FDA) is adding information on severe liver injury to the Boxed Warning of Arava (leflunomide) – a drug used to treat rheumatoid arthritis - to highlight the risk of severe liver injury in patients using this drug and how this risk may be reduced.
>FDA Drug Safety Communication: New risk management plan and patient Medication Guide for Qualaquin (quinine sulfate)[07-08-2010] Due to continued reports of serious side effects in patients using Qualaquin "off-label" (a non-FDA-approved use) for night time leg cramps, the U.S. Food and Drug Administration (FDA) has approved a risk management plan to warn against the use of this drug for such unapproved uses.
FDA News - Business Wire
>U.S. Secretary of Health and Human Services Kathleen Sebelius to Discuss New Report on Medicare Savings by the Centers for Medicare & Medicaid ServicesWASHINGTON--(BUSINESS WIRE)--U.S. Secretary of Health and Human Services Kathleen Sebelius and Director of the Center for Medicare Management for the Centers for Medicare & Medicaid Services (CMS) Jonathan Blum will hold a press conference call at 11:30 a.m. EDT on Monday, Aug. 2, 2010, to discuss a new CMS report on cost-savings for Medicare. WHAT: Press conference call on new report by the Centers for Medicare & Medicaid Services WHO: Kathleen Sebelius, U.S. Secretary of Health and ...
>Lundbeck Inc. Announces the Voluntary Nationwide Recall of Two Lots of NeoProfen® (ibuprofen lysine) InjectionDEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company?s inspections of the two product lots of NeoProfen. The NeoProfen recall, NDC 67386?122-52, includes product lots 1734991 (...
>ArQule, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare ConferenceWOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on August 5, 2010 at 9:30 a.m. The presentation will be web cast live and may be accessed through the investor relations section of the Company?s website, http://www.arqule.com. The BMO conference will be held at the Sheraton New York Hotel and Towers, New York City. About ArQule ArQule is a biotechnology company engage...
>Idaho Technology Issues License to DuPont QualiconSALT LAKE CITY--(BUSINESS WIRE)--Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technol
>ZOLL Propaq MD Monitor/Defibrillator Granted 510(k) Clearance by U.S. Food and Drug AdministrationCHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market and begin distribution of the new Propaq® MD Monitor/Defibrillator that was developed specifically to meet the special needs of military customers and air medical operations worldwide. Development of this product was a joint undertaking between ...
>U.S. Secretary of Health and Human Services Kathleen Sebelius to Discuss New Report on Medicare Savings by the Centers for Medicare & Medicaid ServicesWASHINGTON--(BUSINESS WIRE)--U.S. Secretary of Health and Human Services Kathleen Sebelius and Director of the Center for Medicare Management for the Centers for Medicare & Medicaid Services (CMS) Jonathan Blum will hold a press conference call at 11:30 a.m. EDT on Monday, Aug. 2, 2010, to discuss a new CMS report on cost-savings for Medicare. WHAT: Press conference call on new report by the Centers for Medicare & Medicaid Services WHO: Kathleen Sebelius, U.S. Secretary of Health and ...
>Lundbeck Inc. Announces the Voluntary Nationwide Recall of Two Lots of NeoProfen® (ibuprofen lysine) InjectionDEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company?s inspections of the two product lots of NeoProfen. The NeoProfen recall, NDC 67386?122-52, includes product lots 1734991 (...
>ArQule, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare ConferenceWOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on August 5, 2010 at 9:30 a.m. The presentation will be web cast live and may be accessed through the investor relations section of the Company?s website, http://www.arqule.com. The BMO conference will be held at the Sheraton New York Hotel and Towers, New York City. About ArQule ArQule is a biotechnology company engage...
>Idaho Technology Issues License to DuPont QualiconSALT LAKE CITY--(BUSINESS WIRE)--Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technol
>ZOLL Propaq MD Monitor/Defibrillator Granted 510(k) Clearance by U.S. Food and Drug AdministrationCHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market and begin distribution of the new Propaq® MD Monitor/Defibrillator that was developed specifically to meet the special needs of military customers and air medical operations worldwide. Development of this product was a joint undertaking between ...
FDA Press Releases
>FDA Warns Consumers of Serious Harm from Drinking Miracle Mineral Solution (MMS)The U.S. Food and Drug Administration is warning consumers not to take Miracle Mineral Solution, an oral liquid also known as “Miracle Mineral Supplement” or “MMS.” The product, when used as directed, produces an industrial bleach that can cause serious harm to health.
>FDA Statement on the Reopening of Some La. State Waters to Commercial FishingSTATEMENT BY MARGARET A. HAMBURG, COMMISSIONER OF FOOD AND DRUGS, ON THE REOPENING OF SOME LOUISIANA STATE WATERS TO COMMERCIAL FISHING (HR)
>Former CEO of Seafood Importing Corporation Sentenced to Federal Prison for Importing Falsely Labeled FishFormer CEO of Seafood Importing Corporation Sentenced to Federal Prison for Importing Falsely Labeled Fish
>FDA Approves Drug for Chronic Drooling in ChildrenThe U.S. Food and Drug Administration today approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years.
>New Early Detection System Helps FDA Identify More than 100 Food Safety Problems in First 7 MonthsMore than 100 food safety reports were submitted by industry to the U.S. Food and Drug Administration’s new electronic portal in its first months of operation, the agency said today.
>FDA Warns Consumers of Serious Harm from Drinking Miracle Mineral Solution (MMS)The U.S. Food and Drug Administration is warning consumers not to take Miracle Mineral Solution, an oral liquid also known as “Miracle Mineral Supplement” or “MMS.” The product, when used as directed, produces an industrial bleach that can cause serious harm to health.
>FDA Statement on the Reopening of Some La. State Waters to Commercial FishingSTATEMENT BY MARGARET A. HAMBURG, COMMISSIONER OF FOOD AND DRUGS, ON THE REOPENING OF SOME LOUISIANA STATE WATERS TO COMMERCIAL FISHING (HR)
>Former CEO of Seafood Importing Corporation Sentenced to Federal Prison for Importing Falsely Labeled FishFormer CEO of Seafood Importing Corporation Sentenced to Federal Prison for Importing Falsely Labeled Fish
>FDA Approves Drug for Chronic Drooling in ChildrenThe U.S. Food and Drug Administration today approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years.
>New Early Detection System Helps FDA Identify More than 100 Food Safety Problems in First 7 MonthsMore than 100 food safety reports were submitted by industry to the U.S. Food and Drug Administration’s new electronic portal in its first months of operation, the agency said today.
FDA Vaccines, Blood and Biologics - What's New
>AFLURIA
>FluMist
>Medical Device Recall: Cobe Spectra Apheresis System Disposable Tubing SetsReports of leaks at the return luer connection on two (2) lots of COBE Spectra White Blood Cell disposable tubing sets. WBC Set, Spectra, Functionally closed WBC Set, Spectra.
>GLASSIAAlpha-1-Proteinase Inhibitor (Human)
>CSL Biotherapies Untitled LetterDeviations from current good manufacturing practice (CGMP) requirements in the manufacture of licensed biological vaccine products and monovalent influenza bulks.
>AFLURIA
>FluMist
>Medical Device Recall: Cobe Spectra Apheresis System Disposable Tubing SetsReports of leaks at the return luer connection on two (2) lots of COBE Spectra White Blood Cell disposable tubing sets. WBC Set, Spectra, Functionally closed WBC Set, Spectra.
>GLASSIAAlpha-1-Proteinase Inhibitor (Human)
>CSL Biotherapies Untitled LetterDeviations from current good manufacturing practice (CGMP) requirements in the manufacture of licensed biological vaccine products and monovalent influenza bulks.
FierceBiotech
>FDA lifts hold on Geron studyGeron announced today that the FDA has lifted a clinical hold placed on the company's Investigational New Drug (IND) application, allowing the Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury to proceed. Geron release
>Molineaux turns her attention to start-up CalitheraSusan Molineaux (photo) helped guide cancer drug developer Proteolix from early stage multiple myeloma research through Phase II trials. The developer was snapped up by Onyx Pharmaceuticals, which last year paid $276 million up front for the company, leaving Molineaux free to concentrate on a new project. "I'm a risk taker," Molineaux tells the San Francisco Business Times. "There's probably no super-safe program I've ever been associated with." The entrepreneur has now turned her attention t...
>Sanofi looks beyond blockbusters Sanofi CEO Chris Viebacher (photo) wants his company to avoid the peaks and valleys that come with blockbuster drugs such as Lovenox, a $2 billion-a-year anti-clotting drug that's now facing generic competition. Instead, he's looking at emerging markets, consumer health products and generic medicines to help boost revenue, as well as focusing more on deals for drugs aimed at smaller patient groups. That may help explain Sanofi's interest in Genzyme--a biotech company that makes treatments for...
>Orexigen weight-loss drug shows positive results in studyResults from COR-I, one of the Phase III trials supporting the NDA for Orexigen Therapeutics' (NASDAQ: OREX) weight-loss drug Contrave, show that patients taking the drug were two to three times more likely to lose at least 5 or 10 percent of their body weight compared with those taking placebo. The study results have been published online in the journal Lancet. Treatment with Contrave also resulted in significant improvements versus placebo in waist circumference, insulin resistance, HDL c...
>Charles River, WuXi call off $1.6B dealShareholder opposition has forced Charles River to call off its $1.6 billion plan to purchase China's WuXi PharmaTech. Despite CEO James Foster's assurances that the deal would bring up to $100 million in potential operational savings, several investors were never able to overcome their concerns that the deal wasn't in the company's best interests. Charles River has been expanding its Chinese operations for the past several years and had hoped to increase the size of its footprint in China wi...
>FDA lifts hold on Geron studyGeron announced today that the FDA has lifted a clinical hold placed on the company's Investigational New Drug (IND) application, allowing the Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury to proceed. Geron release
>Molineaux turns her attention to start-up CalitheraSusan Molineaux (photo) helped guide cancer drug developer Proteolix from early stage multiple myeloma research through Phase II trials. The developer was snapped up by Onyx Pharmaceuticals, which last year paid $276 million up front for the company, leaving Molineaux free to concentrate on a new project. "I'm a risk taker," Molineaux tells the San Francisco Business Times. "There's probably no super-safe program I've ever been associated with." The entrepreneur has now turned her attention t...
>Sanofi looks beyond blockbusters Sanofi CEO Chris Viebacher (photo) wants his company to avoid the peaks and valleys that come with blockbuster drugs such as Lovenox, a $2 billion-a-year anti-clotting drug that's now facing generic competition. Instead, he's looking at emerging markets, consumer health products and generic medicines to help boost revenue, as well as focusing more on deals for drugs aimed at smaller patient groups. That may help explain Sanofi's interest in Genzyme--a biotech company that makes treatments for...
>Orexigen weight-loss drug shows positive results in studyResults from COR-I, one of the Phase III trials supporting the NDA for Orexigen Therapeutics' (NASDAQ: OREX) weight-loss drug Contrave, show that patients taking the drug were two to three times more likely to lose at least 5 or 10 percent of their body weight compared with those taking placebo. The study results have been published online in the journal Lancet. Treatment with Contrave also resulted in significant improvements versus placebo in waist circumference, insulin resistance, HDL c...
>Charles River, WuXi call off $1.6B dealShareholder opposition has forced Charles River to call off its $1.6 billion plan to purchase China's WuXi PharmaTech. Despite CEO James Foster's assurances that the deal would bring up to $100 million in potential operational savings, several investors were never able to overcome their concerns that the deal wasn't in the company's best interests. Charles River has been expanding its Chinese operations for the past several years and had hoped to increase the size of its footprint in China wi...
FierceBiotech IT
>NCI plans clinical trial system reformsChange is afoot at the National Cancer Institute, and clinical trials may never be the same again. NCI is becoming more data focused in drug development, according to new leadership, and is taking the clinical trial bull by the horns in wrangling onerous administrative and tech tasks in cooperative trials. Earlier this month, Harold Varmus was sworn in as 14th director of NCI. Varmus, who led NIH from 1993 to 1999, says that first on his list of reforms is the clinical trial system. He refere...
>European academic researchers using CDMSs; Partners combine e-clinical, EHR software;> About 90 percent of European academic research centers have a clinical data management system in use; nearly half are commercial systems. Article > Target Health and LifeOnKey have partnered to combine e-clinical and electronic health record software. Report > Denmark-based CRO BioStata ApS has selected the Veracity EDC platform from KIKA Clinical Solutions in a seven-figure deal. News > Imaging Endpoints, an imaging core lab, has selected the OpenClinica Enterprise Edition as its electroni...
>E-clinical solution adds mobility, language supportTrial enrollment specialist TCN e-Systems has introduced mobility via smartphone to its TrialCentralNet e-clinical solution. The app gives users access to study-goal information, enrollment numbers, key dates, country information, and media metrics through the iPhone and Blackberry. Version 5.2 broadens the solution's language offerings. Those supported are Chinese, Dutch, English, French, German, Hindi, Italian, Japanese, Polish, Portuguese, Russian and Spanish. Release
>Cancer trials halted amid investigationsAlthough modeling and simulation are likely to become fixtures in drug development, they do come with risks. Just ask Duke University. Enrollment has been suspended in three cancer treatment trials and investigators are now reviewing the data amassed from a project to test whether gene expression can help predict tumor response to drugs. The research is based on prediction models whose validity is now as much in question as the academic credentials of the lead researcher, Anil Potti of Duke. ...
>Service locates lost trial subjects, dataAs Avandia maker GlaxoSmithKline (NYSE: GSK) wrestles with the subject and data fallout of the FDA-imposed hold on its TIDE trial, it may want to check in with service provider L2FU, a company that specializes in locating, contacting and collecting data from patients deemed "lost to follow-up." Most trials experience some level of subject disconnects; a clinical trial hold can only boost that level. L2FU, part of recruitment and retention specialist MediciGlobal, recently reported the recover...
>NCI plans clinical trial system reformsChange is afoot at the National Cancer Institute, and clinical trials may never be the same again. NCI is becoming more data focused in drug development, according to new leadership, and is taking the clinical trial bull by the horns in wrangling onerous administrative and tech tasks in cooperative trials. Earlier this month, Harold Varmus was sworn in as 14th director of NCI. Varmus, who led NIH from 1993 to 1999, says that first on his list of reforms is the clinical trial system. He refere...
>European academic researchers using CDMSs; Partners combine e-clinical, EHR software;> About 90 percent of European academic research centers have a clinical data management system in use; nearly half are commercial systems. Article > Target Health and LifeOnKey have partnered to combine e-clinical and electronic health record software. Report > Denmark-based CRO BioStata ApS has selected the Veracity EDC platform from KIKA Clinical Solutions in a seven-figure deal. News > Imaging Endpoints, an imaging core lab, has selected the OpenClinica Enterprise Edition as its electroni...
>E-clinical solution adds mobility, language supportTrial enrollment specialist TCN e-Systems has introduced mobility via smartphone to its TrialCentralNet e-clinical solution. The app gives users access to study-goal information, enrollment numbers, key dates, country information, and media metrics through the iPhone and Blackberry. Version 5.2 broadens the solution's language offerings. Those supported are Chinese, Dutch, English, French, German, Hindi, Italian, Japanese, Polish, Portuguese, Russian and Spanish. Release
>Cancer trials halted amid investigationsAlthough modeling and simulation are likely to become fixtures in drug development, they do come with risks. Just ask Duke University. Enrollment has been suspended in three cancer treatment trials and investigators are now reviewing the data amassed from a project to test whether gene expression can help predict tumor response to drugs. The research is based on prediction models whose validity is now as much in question as the academic credentials of the lead researcher, Anil Potti of Duke. ...
>Service locates lost trial subjects, dataAs Avandia maker GlaxoSmithKline (NYSE: GSK) wrestles with the subject and data fallout of the FDA-imposed hold on its TIDE trial, it may want to check in with service provider L2FU, a company that specializes in locating, contacting and collecting data from patients deemed "lost to follow-up." Most trials experience some level of subject disconnects; a clinical trial hold can only boost that level. L2FU, part of recruitment and retention specialist MediciGlobal, recently reported the recover...
FierceBiotech Research
>Wistar blueprints big expansionThe Wistar Institute plans to knock down part of its cancer research center to make way for a major new addition. Blueprints call for a seven-story research center, the first major expansion to be planned at the site since 1975. Story
>Nasal spray vax for meningitis may offer cheap alternativeScientists at the University of Liverpool have won a hefty new grant to study an experimental nasal spray vaccine that could be used to guard against pneumonia and meningitis. The spray relies on a fragment of a protein found in all types of bacteria pneumococcus. "Babies and children are vulnerable to infections," says Dr. Yolande Harley. "Meningitis and septicemia...kill significant numbers of children in the UK each year. This is an important area of research which has the potential to pro...
>"Longevity gene" used to cure Alzheimer's in miceA group of biologists at MIT say they have nailed down solid evidence from an animal study that the SIRT1 pathway can be used to successfully treat Alzheimer's. In a study of mice modeled to suffer from Alzheimer's while producing higher levels of sirtuin one, the scientists found that the rodents retained both memory and learning abilities, warding off the disease. "This is the first demonstration that the SIRT1 pathway can mitigate Alzheimer's," Leonard Guarente, a biologist at MIT, tells t...
>Researchers ID a key culprit in the aging processAging researchers have long understood that human cells can only replicate themselves a finite number of times. Now a group of researchers at the Stowers Institute in Kansas City say they have identified a key protein that helps explain why that mechanism is limited, and what determines when an organism will die. And their study has implications both for aging as well as cancer research. Rong Li, a cell biologist at the Stowers Institute, focused on multidrug resistant proteins (MDRs), which ...
>Study: Animal molecule in drugs triggers immune responseDrugs used to treat serious diseases contain an animal molecule that can harm the health of some patients, according to a team led by Professor Ajit Varki. Sialic acids are in all mammals, but humans lack a specific type--Neu5Gc--that is found in many other mammals. Neu5Gc can enter the human body through modern biotech drugs that come from animal sources--and also through the consumption of red meat--and trigger an immune response that can have a damaging inflammatory effect in some individu...
>Wistar blueprints big expansionThe Wistar Institute plans to knock down part of its cancer research center to make way for a major new addition. Blueprints call for a seven-story research center, the first major expansion to be planned at the site since 1975. Story
>Nasal spray vax for meningitis may offer cheap alternativeScientists at the University of Liverpool have won a hefty new grant to study an experimental nasal spray vaccine that could be used to guard against pneumonia and meningitis. The spray relies on a fragment of a protein found in all types of bacteria pneumococcus. "Babies and children are vulnerable to infections," says Dr. Yolande Harley. "Meningitis and septicemia...kill significant numbers of children in the UK each year. This is an important area of research which has the potential to pro...
>"Longevity gene" used to cure Alzheimer's in miceA group of biologists at MIT say they have nailed down solid evidence from an animal study that the SIRT1 pathway can be used to successfully treat Alzheimer's. In a study of mice modeled to suffer from Alzheimer's while producing higher levels of sirtuin one, the scientists found that the rodents retained both memory and learning abilities, warding off the disease. "This is the first demonstration that the SIRT1 pathway can mitigate Alzheimer's," Leonard Guarente, a biologist at MIT, tells t...
>Researchers ID a key culprit in the aging processAging researchers have long understood that human cells can only replicate themselves a finite number of times. Now a group of researchers at the Stowers Institute in Kansas City say they have identified a key protein that helps explain why that mechanism is limited, and what determines when an organism will die. And their study has implications both for aging as well as cancer research. Rong Li, a cell biologist at the Stowers Institute, focused on multidrug resistant proteins (MDRs), which ...
>Study: Animal molecule in drugs triggers immune responseDrugs used to treat serious diseases contain an animal molecule that can harm the health of some patients, according to a team led by Professor Ajit Varki. Sialic acids are in all mammals, but humans lack a specific type--Neu5Gc--that is found in many other mammals. Neu5Gc can enter the human body through modern biotech drugs that come from animal sources--and also through the consumption of red meat--and trigger an immune response that can have a damaging inflammatory effect in some individu...
FiercePharma
>Dutch labor leaders sue Merck over job cutsThe works council of Merck's (NYSE: MRK) Dutch R&D operations is taking the U.S. pharmaceutical firm to court over planned job cuts in the Netherlands, a works council spokesman said Friday. Report
>Astellas to shutter NY facilities, cut jobsAstellas Pharma is the latest drugmaker to plan a shutdown of U.S. facilities. The Japanese company will shutter operations in Ardsley and Melville, NY, both of which it acquired in the $4 billion buyout of OSI Pharmaceuticals, Dow Jones reports. Roughly 150 workers are employed at the sites, which will close by June 2011. Astellas snapped up OSI (NASDAQ: OSIP) in a hostile bid, aiming to gain the latter's blockbuster cancer drug Tarceva. OSI also had operations in Farmingdale, N.Y., and Ceda...
>Big Pharma's Q2 2010 Earnings ReportNeed a Big Pharma financial fix? Look no further. FiercePharma is launching a new feature to help you keep track of drugmakers' quarterly results. We've compiled earnings reports from the top 10 companies in pharma, as ranked by 2009 revenues. Each profile includes earnings summaries, quick factoids on the numbers, and links to company news. Check out the list below, or click through any of our reports on these companies. Earnings reports >>
>Merck, Amgen's falling profits still beat StreetEarnings season continues with a couple of biggies: Merck unveiled profits that suffered from merger-and-restructuring charges, and Amgen reported street-beating earnings despite some sales declines. Meanwhile, two Japanese drugmakers posted mixed results. Here are the highlights: Merck reported a 52 percent decline in second-quarter profit, as merger-related and restructuring costs more than offset a near doubling in sales as a result of its takeover of Schering-Plough. But without those on...
>Would-be whistleblower sues Bayer over firingPharma whistleblowers aren't just focused on alleged marketing shenanigans. Arcane accounting rules gets attention too. This time, the company is Bayer, and the whistleblower raised the red flag over compliance with the very complicated Sarbanes-Oxley Act. In a federal lawsuit, plaintiff Ralph Fabiano claims that a senior Bayer executive told him to falsify the results of certain auditing and accounting tests, and he refused. After refusing repeatedly, he was fired, the suit alleges. And that...
>Dutch labor leaders sue Merck over job cutsThe works council of Merck's (NYSE: MRK) Dutch R&D operations is taking the U.S. pharmaceutical firm to court over planned job cuts in the Netherlands, a works council spokesman said Friday. Report
>Astellas to shutter NY facilities, cut jobsAstellas Pharma is the latest drugmaker to plan a shutdown of U.S. facilities. The Japanese company will shutter operations in Ardsley and Melville, NY, both of which it acquired in the $4 billion buyout of OSI Pharmaceuticals, Dow Jones reports. Roughly 150 workers are employed at the sites, which will close by June 2011. Astellas snapped up OSI (NASDAQ: OSIP) in a hostile bid, aiming to gain the latter's blockbuster cancer drug Tarceva. OSI also had operations in Farmingdale, N.Y., and Ceda...
>Big Pharma's Q2 2010 Earnings ReportNeed a Big Pharma financial fix? Look no further. FiercePharma is launching a new feature to help you keep track of drugmakers' quarterly results. We've compiled earnings reports from the top 10 companies in pharma, as ranked by 2009 revenues. Each profile includes earnings summaries, quick factoids on the numbers, and links to company news. Check out the list below, or click through any of our reports on these companies. Earnings reports >>
>Merck, Amgen's falling profits still beat StreetEarnings season continues with a couple of biggies: Merck unveiled profits that suffered from merger-and-restructuring charges, and Amgen reported street-beating earnings despite some sales declines. Meanwhile, two Japanese drugmakers posted mixed results. Here are the highlights: Merck reported a 52 percent decline in second-quarter profit, as merger-related and restructuring costs more than offset a near doubling in sales as a result of its takeover of Schering-Plough. But without those on...
>Would-be whistleblower sues Bayer over firingPharma whistleblowers aren't just focused on alleged marketing shenanigans. Arcane accounting rules gets attention too. This time, the company is Bayer, and the whistleblower raised the red flag over compliance with the very complicated Sarbanes-Oxley Act. In a federal lawsuit, plaintiff Ralph Fabiano claims that a senior Bayer executive told him to falsify the results of certain auditing and accounting tests, and he refused. After refusing repeatedly, he was fired, the suit alleges. And that...
FiercePharma Manufacturing
>FDA joins Tox21 collaborationThe FDA has signed on with the Tox21 collaboration. The regulator joins the EPA, the National Institute of Environmental Health Sciences National Toxicology Program, and the National Institute of Health Chemical Genomics Center in developing models to predict how chemicals will affect human health and the environment. Release
>Oracle debuts pedigree productOracle has announced the availability of Pedigree and Serialization Manager, a mass-serialization and pedigree application. The solution generates, stores, transmits and authenticates drug product serial data and ePedigree data as products traverse the supply chain, according to the company. In addition to its counterfeit threat identification capabilities, the product can aid in compliance and returns management. The offering uses an open standards-based Service Oriented Architecture and Ora...
>Warning letter delineates brandholder/CMO rolesDespite having developed new procedures for product approval processes and promising to review its validation program with contract manufacturers, complete vendor audits and conduct annual product reviews, River's Edge Pharmaceuticals in Suwanee, GA, has still come up lacking by FDA standards. The regulator says in Warning Letter 10-ALT-15 that it acknowledges these efforts. "However, we are concerned about your firm's fundamental understanding of what is required by your [quality control uni...
>Merck supply issues delay hep B vax in CanadaSupply issues have left Canadian adults short of hepatitis B protection. Merck says the vaccine will likely be unavailable for the rest of the year, and GlaxoSmithKline is attempting to cover the shortfall. A Merck spokesperson says in a press report that "supply disruptions have occurred due to unexpected manufacturing issues that prompted modification to some of our processes and equipment." The matter stretches back to January 2009 when the drug giant said it was upgrading equipment at a W...
>FDA softens tone when addressing unapproved drugs Like Cody Labs, River's Edge Pharmaceuticals is in hot water for the manufacture and distribution of unapproved drugs. In fact, it's one of several topics covered in Warning Letter 10-ATL-15. However, the careful reader may detect a note of helpfulness when unapproved drugs are concerned. "FDA understands the need for assistance when securing approval for currently marketed unapproved drugs," the letter says. "As part of our commitment to assist firms through this process, FDA has appointed a...
>FDA joins Tox21 collaborationThe FDA has signed on with the Tox21 collaboration. The regulator joins the EPA, the National Institute of Environmental Health Sciences National Toxicology Program, and the National Institute of Health Chemical Genomics Center in developing models to predict how chemicals will affect human health and the environment. Release
>Oracle debuts pedigree productOracle has announced the availability of Pedigree and Serialization Manager, a mass-serialization and pedigree application. The solution generates, stores, transmits and authenticates drug product serial data and ePedigree data as products traverse the supply chain, according to the company. In addition to its counterfeit threat identification capabilities, the product can aid in compliance and returns management. The offering uses an open standards-based Service Oriented Architecture and Ora...
>Warning letter delineates brandholder/CMO rolesDespite having developed new procedures for product approval processes and promising to review its validation program with contract manufacturers, complete vendor audits and conduct annual product reviews, River's Edge Pharmaceuticals in Suwanee, GA, has still come up lacking by FDA standards. The regulator says in Warning Letter 10-ALT-15 that it acknowledges these efforts. "However, we are concerned about your firm's fundamental understanding of what is required by your [quality control uni...
>Merck supply issues delay hep B vax in CanadaSupply issues have left Canadian adults short of hepatitis B protection. Merck says the vaccine will likely be unavailable for the rest of the year, and GlaxoSmithKline is attempting to cover the shortfall. A Merck spokesperson says in a press report that "supply disruptions have occurred due to unexpected manufacturing issues that prompted modification to some of our processes and equipment." The matter stretches back to January 2009 when the drug giant said it was upgrading equipment at a W...
>FDA softens tone when addressing unapproved drugs Like Cody Labs, River's Edge Pharmaceuticals is in hot water for the manufacture and distribution of unapproved drugs. In fact, it's one of several topics covered in Warning Letter 10-ATL-15. However, the careful reader may detect a note of helpfulness when unapproved drugs are concerned. "FDA understands the need for assistance when securing approval for currently marketed unapproved drugs," the letter says. "As part of our commitment to assist firms through this process, FDA has appointed a...
FierceVaccines
>Biovest wins orphan drug status for cancer vaxBiovest International has announced that the FDA has granted orphan drug designation to BiovaxID, its personalized cancer vaccine, for a second lymphoma indication. "With promising clinical trials now complete in both follicular lymphoma and mantle cell lymphoma, we are preparing to seek regulatory approvals for BiovaxID in two separate indications," says Dr. Carlos Santos, Biovest's VP, product development & regulatory affairs. Release
>Merck, Sanofi outline plans for new animal health JVThe newly created Merial-Intervet is being forged by Merck and Sanofi-Aventis into a global powerhouse in the animal health industry, and it will rely heavily on income from some best-selling vaccines to garner an expected $5 billion in annual sales. The company will sell Recombitek, a vaccine that guards horses against West Nile virus, Eclipse for cats and Galaxy for dogs, among other shots. Earlier this week, the two pharma companies tapped the new CEO of the JV: Raul Kohan, currently presi...
>NEJM lays out questions--and facts--about ProvengeShares of Dendreon (NASDAQ: DNDN) soared into the stratosphere in the lead-up to Provenge's approval--and then promptly started tumbling fast as all sorts of questions arose about supply issues and efficacy. The company is likely to benefit enormously from the publication of its biggest study of the innovative prostate cancer vaccine in the prestigious New England Journal of Medicine, which carries biblical weight with providers. The facts about the Provenge data have been known for some time...
>Vaccination gaps contribute to pertussis outbreakOver the past few years, safety fears have caused some parents to refuse to get their children vaccinated against certain diseases. And some believe failure to do so may have contributed to a whooping cough (pertussis) outbreak in California that may become the worst 50 years. Experts say there is no single factor contributing to the rise of pertussis cases. However, in addition to some parents refusing vaccines, a number of doctors aren't offering all the recommended immunizations because of...
>Vax nanopatch offers stick-on alternative to a needleDuring the next pandemic, people may be able to get their vaccines delivered in the mail rather than having to wait in line for a jab. Prof. Mark Kendall of the Australian Institute for Biotechnology and Nanotechnology says he has developed a nanopatch no bigger than a postage stamp that can be used to deliver a vaccine. And unlike most vaccines today, it doesn't need to be refrigerated, and it eliminates any nasty injuries caused by injections. "The World Health Organization estimates that 3...
>Biovest wins orphan drug status for cancer vaxBiovest International has announced that the FDA has granted orphan drug designation to BiovaxID, its personalized cancer vaccine, for a second lymphoma indication. "With promising clinical trials now complete in both follicular lymphoma and mantle cell lymphoma, we are preparing to seek regulatory approvals for BiovaxID in two separate indications," says Dr. Carlos Santos, Biovest's VP, product development & regulatory affairs. Release
>Merck, Sanofi outline plans for new animal health JVThe newly created Merial-Intervet is being forged by Merck and Sanofi-Aventis into a global powerhouse in the animal health industry, and it will rely heavily on income from some best-selling vaccines to garner an expected $5 billion in annual sales. The company will sell Recombitek, a vaccine that guards horses against West Nile virus, Eclipse for cats and Galaxy for dogs, among other shots. Earlier this week, the two pharma companies tapped the new CEO of the JV: Raul Kohan, currently presi...
>NEJM lays out questions--and facts--about ProvengeShares of Dendreon (NASDAQ: DNDN) soared into the stratosphere in the lead-up to Provenge's approval--and then promptly started tumbling fast as all sorts of questions arose about supply issues and efficacy. The company is likely to benefit enormously from the publication of its biggest study of the innovative prostate cancer vaccine in the prestigious New England Journal of Medicine, which carries biblical weight with providers. The facts about the Provenge data have been known for some time...
>Vaccination gaps contribute to pertussis outbreakOver the past few years, safety fears have caused some parents to refuse to get their children vaccinated against certain diseases. And some believe failure to do so may have contributed to a whooping cough (pertussis) outbreak in California that may become the worst 50 years. Experts say there is no single factor contributing to the rise of pertussis cases. However, in addition to some parents refusing vaccines, a number of doctors aren't offering all the recommended immunizations because of...
>Vax nanopatch offers stick-on alternative to a needleDuring the next pandemic, people may be able to get their vaccines delivered in the mail rather than having to wait in line for a jab. Prof. Mark Kendall of the Australian Institute for Biotechnology and Nanotechnology says he has developed a nanopatch no bigger than a postage stamp that can be used to deliver a vaccine. And unlike most vaccines today, it doesn't need to be refrigerated, and it eliminates any nasty injuries caused by injections. "The World Health Organization estimates that 3...
Health News - BizJournals.com
>Business groups still fighting health care reformBusiness groups that opposed health care reform are working to undo parts of the new law, even before it is implemented.
>Hospice of Hilo plans to finish facilityHospice of Hilo plans to complete a $10 million in-patient facility in Hilo later this year, the only one of its kind on a Neighbor Island.
>NLRB sets Sept. 13 as start for giant Kaiser Permanente union electionThe National Labor Relations Board has set Sept. 13 as the start date for a by-mail union representation election at Kaiser Permanente, according to the National Union of Healthcare Workers, one of the unions that will take part in the balloting.
>Independence Center gets $50,000 Anthem giftThe Anthem Blue Cross and Blue Shield Foundation in Missouri awarded $51,479 to Independence Center, a nonprofit agency serving St. Louis-area adults with serious and persistent mental illnesses. (WLP)
>HealthSouth to build hospital in CypressHealthSouth Corp. is beginning construction on a new 40-bed inpatient rehabilitation hospital in the Cypress area. (HLS)
>Business groups still fighting health care reformBusiness groups that opposed health care reform are working to undo parts of the new law, even before it is implemented.
>Hospice of Hilo plans to finish facilityHospice of Hilo plans to complete a $10 million in-patient facility in Hilo later this year, the only one of its kind on a Neighbor Island.
>NLRB sets Sept. 13 as start for giant Kaiser Permanente union electionThe National Labor Relations Board has set Sept. 13 as the start date for a by-mail union representation election at Kaiser Permanente, according to the National Union of Healthcare Workers, one of the unions that will take part in the balloting.
>Independence Center gets $50,000 Anthem giftThe Anthem Blue Cross and Blue Shield Foundation in Missouri awarded $51,479 to Independence Center, a nonprofit agency serving St. Louis-area adults with serious and persistent mental illnesses. (WLP)
>HealthSouth to build hospital in CypressHealthSouth Corp. is beginning construction on a new 40-bed inpatient rehabilitation hospital in the Cypress area. (HLS)
Health News - CNBC
>Group: Enough signers for vote on ND pharmacy lawA group seeking to repeal North Dakota's pharmacy ownership law has gathered enough signatures to put the issue on the November ballot, a spokeswoman said.
>Teva: Canadian regulators clear Ratiopharm dealIsraeli drug maker Teva Pharmaceutical Industries Ltd. said Friday that Canadian antitrust regulators have cleared the company's acquisition of Ratiopharm, owned by the Merckle family.
>Conatus acquires Pfizer subsidiary IdunPrivately held Conatus Pharmaceuticals Inc. said Friday it has acquired Pfizer Inc. subsidiary Idun Pharmaceuticals for an undisclosed sum.
>Ziopharm swings to 2Q profit on non-cash gainZiopharm Oncology Inc. said Friday that it turned a second-quarter profit on a $14.1 million gain in non-cash warrant income.
>Aetna board authorizes $1B share repurchase planHealth insurer Aetna Inc. said Friday its board of directors has authorized it to buy back up to $1 billion of its common stock, a move that will boost per-share earnings and expand the percentage of shareholders' stakes.
>Group: Enough signers for vote on ND pharmacy lawA group seeking to repeal North Dakota's pharmacy ownership law has gathered enough signatures to put the issue on the November ballot, a spokeswoman said.
>Teva: Canadian regulators clear Ratiopharm dealIsraeli drug maker Teva Pharmaceutical Industries Ltd. said Friday that Canadian antitrust regulators have cleared the company's acquisition of Ratiopharm, owned by the Merckle family.
>Conatus acquires Pfizer subsidiary IdunPrivately held Conatus Pharmaceuticals Inc. said Friday it has acquired Pfizer Inc. subsidiary Idun Pharmaceuticals for an undisclosed sum.
>Ziopharm swings to 2Q profit on non-cash gainZiopharm Oncology Inc. said Friday that it turned a second-quarter profit on a $14.1 million gain in non-cash warrant income.
>Aetna board authorizes $1B share repurchase planHealth insurer Aetna Inc. said Friday its board of directors has authorized it to buy back up to $1 billion of its common stock, a move that will boost per-share earnings and expand the percentage of shareholders' stakes.
Health News - Fox Business
>Arena Rises As Editorial Raises Questions About RivalArena Rises As Editorial Raises Questions About Rival
>MARKET SNAPSHOT: U.S. Stocks End July With Strong GainsMARKET SNAPSHOT: U.S. Stocks End July With Strong Gains
>CVS Caremark Drug-Benefit Turnaround Tied To Sharper MarketingCVS Caremark Drug-Benefit Turnaround Tied To Sharper Marketing
>Warner Chilcott Shares Up on Recapitalization PlanWarner Chilcott (NASDAQ:WCRX), a specialty pharmaceutical company, shot into the green nearly 6% Friday after it announced a recapitalization plan where it intends to incur $2.25 billion of new debt to fund a special dividend to its shareholders before the end of the third quarter.
>FDA Approves Vaccines for 2010-11 Flu SeasonFDA Approves Vaccines for 2010-11 Flu Season
>Arena Rises As Editorial Raises Questions About RivalArena Rises As Editorial Raises Questions About Rival
>MARKET SNAPSHOT: U.S. Stocks End July With Strong GainsMARKET SNAPSHOT: U.S. Stocks End July With Strong Gains
>CVS Caremark Drug-Benefit Turnaround Tied To Sharper MarketingCVS Caremark Drug-Benefit Turnaround Tied To Sharper Marketing
>Warner Chilcott Shares Up on Recapitalization PlanWarner Chilcott (NASDAQ:WCRX), a specialty pharmaceutical company, shot into the green nearly 6% Friday after it announced a recapitalization plan where it intends to incur $2.25 billion of new debt to fund a special dividend to its shareholders before the end of the third quarter.
>FDA Approves Vaccines for 2010-11 Flu SeasonFDA Approves Vaccines for 2010-11 Flu Season
Marketwire - Pharma and Biotech
>MethylGene pr?nte ses r?ltats financiers du deuxi? trimestre de l'exercice 2010 ainsi qu'une mise ?our d'ordre clinique sur le MGCD265 MONTR?L, QU?EC--(Marketwire - 30 juillet 2010) - MethylGene Inc. (TSX:MYG) annonce aujourd'hui ses r?ltats financiers du deuxi? trimestre termin?e 30 juin 2010. La Soci? pr?nte de plus une mise ?our d'ordre clinique sur son inhibiteur de kinases (Met) ?ibles multiples contre le cancer, le MGCD265.
>MethylGene Reports Second Quarter 2010 Financial Results and Provides Clinical Update for MGCD265 MONTREAL, QUEBEC--(Marketwire - July 30, 2010) - MethylGene Inc. (TSX:MYG) today announced financial results for the second quarter ended June 30, 2010. In addition, the Company provided a clinical trial update for its multi-targeted (Met) kinase oncology inhibitor, MGCD265. Financial Results Reported in Canadian Dollars
>Save the Children Mobilizing to Help Families Affected by Pakistan FloodingWESTPORT, CT--(Marketwire - July 30, 2010) - Save the Children is mobilizing supplies and personnel to begin providing emergency assistance to the families who have been affected by the unusually heavy monsoon rains in Pakistan. More than 400 people have died since the rains began 10 days ago, many in parts of Swat Valley and the districts of Shangla and Tank, where floodwaters have swept away hundreds of mud houses. Rushing water has also washed away thousands of acres of crops and dozens o...
>Dynavax Reports 2010 Second Quarter Financial ResultsBERKELEY, CA--(Marketwire - July 30, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2010, including $57.4 million in cash and cash equivalents. This compared to $30.1 million at March 31, 2010. In April, the Company completed a financing which resulted in net proceeds of $41 million. The $13.7 million cash usage for the second quarter primarily reflected accelerated enrollment and immunization of over 2,400 subje...
>Kahn Swick & Foti, LLC and Former Louisiana Attorney General Notify XenoPort Shareholders of Class Action Securities Fraud on Behalf of XNPT Shareholders From May 5, 2009 to February 17, 2010 - XNPTNEW ORLEANS, LA--(Marketwire - July 30, 2010) - Kahn Swick & Foti, LLC ("KSF") (www.ksfcounsel.com), a nationally recognized Louisiana-based law firm with offices also in New York, and KSF partner Charles C. Foti, Jr., former Attorney General of Louisiana, announce that a class action has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of XenoPort, Inc. ("XenoPort") (NASDAQ: XNPT) common stock during the period between May 5,...
>MethylGene pr?nte ses r?ltats financiers du deuxi? trimestre de l'exercice 2010 ainsi qu'une mise ?our d'ordre clinique sur le MGCD265 MONTR?L, QU?EC--(Marketwire - 30 juillet 2010) - MethylGene Inc. (TSX:MYG) annonce aujourd'hui ses r?ltats financiers du deuxi? trimestre termin?e 30 juin 2010. La Soci? pr?nte de plus une mise ?our d'ordre clinique sur son inhibiteur de kinases (Met) ?ibles multiples contre le cancer, le MGCD265.
>MethylGene Reports Second Quarter 2010 Financial Results and Provides Clinical Update for MGCD265 MONTREAL, QUEBEC--(Marketwire - July 30, 2010) - MethylGene Inc. (TSX:MYG) today announced financial results for the second quarter ended June 30, 2010. In addition, the Company provided a clinical trial update for its multi-targeted (Met) kinase oncology inhibitor, MGCD265. Financial Results Reported in Canadian Dollars
>Save the Children Mobilizing to Help Families Affected by Pakistan FloodingWESTPORT, CT--(Marketwire - July 30, 2010) - Save the Children is mobilizing supplies and personnel to begin providing emergency assistance to the families who have been affected by the unusually heavy monsoon rains in Pakistan. More than 400 people have died since the rains began 10 days ago, many in parts of Swat Valley and the districts of Shangla and Tank, where floodwaters have swept away hundreds of mud houses. Rushing water has also washed away thousands of acres of crops and dozens o...
>Dynavax Reports 2010 Second Quarter Financial ResultsBERKELEY, CA--(Marketwire - July 30, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2010, including $57.4 million in cash and cash equivalents. This compared to $30.1 million at March 31, 2010. In April, the Company completed a financing which resulted in net proceeds of $41 million. The $13.7 million cash usage for the second quarter primarily reflected accelerated enrollment and immunization of over 2,400 subje...
>Kahn Swick & Foti, LLC and Former Louisiana Attorney General Notify XenoPort Shareholders of Class Action Securities Fraud on Behalf of XNPT Shareholders From May 5, 2009 to February 17, 2010 - XNPTNEW ORLEANS, LA--(Marketwire - July 30, 2010) - Kahn Swick & Foti, LLC ("KSF") (www.ksfcounsel.com), a nationally recognized Louisiana-based law firm with offices also in New York, and KSF partner Charles C. Foti, Jr., former Attorney General of Louisiana, announce that a class action has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of XenoPort, Inc. ("XenoPort") (NASDAQ: XNPT) common stock during the period between May 5,...
MassBio News
>MassBio President Bob Coughlin speaks about the Co-Pay Assistance Bill on Greater Boston (WGBH) MassBio President Bob Coughlin explains how this bill will help the patient population of Massachusetts.
>MassBio President Bob Coughlin speaks about the Pharmaceutical Coupon Bill with Greater Boston on WGBH A piece of legislation in the Massachusetts legislature known as the Coupon Bill would lift a decades-old ban on pharma-manufacturer discounts and would allow drug companies to subsidize the cost of expensive medications through a coupon program. Supports say it would offset the high cost of life-saving medications, but opponents say it?s a marketing ploy by pharmaceutical companies to get patients hooked on expensive brand name drugs.
>FDA, CMS Memorandum of Understanding ReleasedThe FDA and CMS have released their Memorandum of Understanding (MOU). The text is below and can also be found online here. MEMORANDUM OF UNDERSTANDINGBETWEENUNITED STATES FOOD AND DRUG ADMINISTRATIONANDCENTERS FOR MEDICARE & MEDICAID SERVICES 1. Preamble The Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS), both as part of the Department of Health and Human Services, and hereinafter also referred to as "Federal partners," agree to work together t...
>Gaming for Good at Summer CampMicrosoft, MassBioEd and Children?s Hospital Boston Host Week-long Learning Video Game Camp for Massachusetts Students School?s out and few students statewide will be able to say they spent a week of their summer vacation learning how to develop a video game from industry leaders from the MIT Education Arcade, the Learning Games Network and FableVision. Generation Cures at Children?s Hospital Boston, Microsoft and the Massachusetts Biotechnology Education Foundation (MassBioEd) are hostin...
>International partnership brings fresh facesFrom the Summer 2010 issue of the MassBio News There will be four new faces at the Novartis labs in Cambridge this summer, as part of an international partnership with the non-profit Seeding Labs and Kenyatta University. Drs. Sauda Swaleh, Hudson Nyambaka, Nicholas Gikonyo and Evans Changamu , from the university?s pharmacy and chemistry departments, will spend 10 weeks shadowing Novartis scientists, discussing issues like intellectual property and networking with their American counte...
>MassBio President Bob Coughlin speaks about the Co-Pay Assistance Bill on Greater Boston (WGBH) MassBio President Bob Coughlin explains how this bill will help the patient population of Massachusetts.
>MassBio President Bob Coughlin speaks about the Pharmaceutical Coupon Bill with Greater Boston on WGBH A piece of legislation in the Massachusetts legislature known as the Coupon Bill would lift a decades-old ban on pharma-manufacturer discounts and would allow drug companies to subsidize the cost of expensive medications through a coupon program. Supports say it would offset the high cost of life-saving medications, but opponents say it?s a marketing ploy by pharmaceutical companies to get patients hooked on expensive brand name drugs.
>FDA, CMS Memorandum of Understanding ReleasedThe FDA and CMS have released their Memorandum of Understanding (MOU). The text is below and can also be found online here. MEMORANDUM OF UNDERSTANDINGBETWEENUNITED STATES FOOD AND DRUG ADMINISTRATIONANDCENTERS FOR MEDICARE & MEDICAID SERVICES 1. Preamble The Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS), both as part of the Department of Health and Human Services, and hereinafter also referred to as "Federal partners," agree to work together t...
>Gaming for Good at Summer CampMicrosoft, MassBioEd and Children?s Hospital Boston Host Week-long Learning Video Game Camp for Massachusetts Students School?s out and few students statewide will be able to say they spent a week of their summer vacation learning how to develop a video game from industry leaders from the MIT Education Arcade, the Learning Games Network and FableVision. Generation Cures at Children?s Hospital Boston, Microsoft and the Massachusetts Biotechnology Education Foundation (MassBioEd) are hostin...
>International partnership brings fresh facesFrom the Summer 2010 issue of the MassBio News There will be four new faces at the Novartis labs in Cambridge this summer, as part of an international partnership with the non-profit Seeding Labs and Kenyatta University. Drs. Sauda Swaleh, Hudson Nyambaka, Nicholas Gikonyo and Evans Changamu , from the university?s pharmacy and chemistry departments, will spend 10 weeks shadowing Novartis scientists, discussing issues like intellectual property and networking with their American counte...
Medical Pharma - PR Newswire
>NLRB Decision Supports Quincy Medical Center in Negotiations with NursesQUINCY, Mass., July 31 /PRNewswire/ -- The National Labor Relations Board has determined that Quincy Medical Center "bargained in good faith" in its recent negotiations with the Massachusetts Nursing Association and management's decision to declare an impasse and implement its final proposals was la
>WellPoint Announces Appearance at Upcoming ConferenceINDIANAPOLIS, July 30 /PRNewswire-FirstCall/ -- WellPoint, Inc. (NYSE: WLP) announced today that senior management is scheduled to present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on August 5, 2010, at 3:00 p.m. Eastern Daylight Time. All interested parties are invited t
>CareFusion Will Host an Earnings Conference Call on Aug. 10 to Discuss the Results for the Fourth Quarter and Fiscal 2010SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- CareFusion Corporation (NYSE: CFN) today announced plans to release fourth quarter and fiscal 2010 results on Tuesday, Aug. 10 following the close of trading on the New York Stock Exchange. The company will host a webcast and conference call on Aug. 10 at
>Fred Hutchinson Cancer Research Center Announces Selection of Its New President and DirectorSEATTLE, July 30 /PRNewswire/ -- The Fred Hutchinson Cancer Research Center board of trustees today announced the selection of Lawrence Corey, M.D., an internationally renowned expert in virology, immunology and vaccine development, as its new president and director. He is expected to begin responsi
>World-Class Eye Doctor Donates Procedure to All-Star's CharityWAYNE, Pa., July 30 /PRNewswire/ -- Steven Siepser, M.D., one of the Delaware Valley's most distinguished ophthalmologists, is donating a Lasik eye procedure to the Shane Victorino Foundation. Dr. Siepser's donation is part of the foundation's All-Star Celebrity Fashion Show, a benefit dinner inclu
>NLRB Decision Supports Quincy Medical Center in Negotiations with NursesQUINCY, Mass., July 31 /PRNewswire/ -- The National Labor Relations Board has determined that Quincy Medical Center "bargained in good faith" in its recent negotiations with the Massachusetts Nursing Association and management's decision to declare an impasse and implement its final proposals was la
>WellPoint Announces Appearance at Upcoming ConferenceINDIANAPOLIS, July 30 /PRNewswire-FirstCall/ -- WellPoint, Inc. (NYSE: WLP) announced today that senior management is scheduled to present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on August 5, 2010, at 3:00 p.m. Eastern Daylight Time. All interested parties are invited t
>CareFusion Will Host an Earnings Conference Call on Aug. 10 to Discuss the Results for the Fourth Quarter and Fiscal 2010SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- CareFusion Corporation (NYSE: CFN) today announced plans to release fourth quarter and fiscal 2010 results on Tuesday, Aug. 10 following the close of trading on the New York Stock Exchange. The company will host a webcast and conference call on Aug. 10 at
>Fred Hutchinson Cancer Research Center Announces Selection of Its New President and DirectorSEATTLE, July 30 /PRNewswire/ -- The Fred Hutchinson Cancer Research Center board of trustees today announced the selection of Lawrence Corey, M.D., an internationally renowned expert in virology, immunology and vaccine development, as its new president and director. He is expected to begin responsi
>World-Class Eye Doctor Donates Procedure to All-Star's CharityWAYNE, Pa., July 30 /PRNewswire/ -- Steven Siepser, M.D., one of the Delaware Valley's most distinguished ophthalmologists, is donating a Lasik eye procedure to the Shane Victorino Foundation. Dr. Siepser's donation is part of the foundation's All-Star Celebrity Fashion Show, a benefit dinner inclu
National Center for Biotechnology Information
>dbGaP News and AnnouncementsBrief news and announcements from dbGaP, the database of Genotypes and Phenotypes.
>NCBI NewsAnnouncements regarding major chanages and updates to NCBI resources and tools.
>Bookshelf NewsBrief Announcements highlighting new books and features added to the NCBI Books database.
>dbVar News and AnnouncementsBrief news and announcements from dbVar, a database of genomic structural variants.
>Genome Reference Consortium NewsGenome reference consortium news.
>dbGaP News and AnnouncementsBrief news and announcements from dbGaP, the database of Genotypes and Phenotypes.
>NCBI NewsAnnouncements regarding major chanages and updates to NCBI resources and tools.
>Bookshelf NewsBrief Announcements highlighting new books and features added to the NCBI Books database.
>dbVar News and AnnouncementsBrief news and announcements from dbVar, a database of genomic structural variants.
>Genome Reference Consortium NewsGenome reference consortium news.
Nature Biotechnology
>Sunshine on conflictsUS drug companies are preparing for new draconian provisions for reporting on financial relationships with academia. Will efforts to increase transparency prove burdensome to researchers and the industry? Virginia Hughes investigates.
>Ask your doctorWhen seeking a licensing partner for a product in development, market projections and strategies require substantiation. This can be provided through physician interviews.
>PeptideClassifier for protein inference and targeted quantitative proteomics
>Minimum information about a protein affinity reagent (MIAPAR)
>Merck ditches biogeneric
>Sunshine on conflictsUS drug companies are preparing for new draconian provisions for reporting on financial relationships with academia. Will efforts to increase transparency prove burdensome to researchers and the industry? Virginia Hughes investigates.
>Ask your doctorWhen seeking a licensing partner for a product in development, market projections and strategies require substantiation. This can be provided through physician interviews.
>PeptideClassifier for protein inference and targeted quantitative proteomics
>Minimum information about a protein affinity reagent (MIAPAR)
>Merck ditches biogeneric
New York Times- Biotechnology
>Europe Clears Import of New Biotech Corn VarietiesThe European Commission approved six genetically modified corn varieties for import to the bloc in another sign of its desire to speed up decision-making on the controversial technology.
>Exploring Algae as FuelDozens of bioengineering laboratories are trying to create superalgae that can be used to make diesel or jet fuel.
>Europeans Seek to Ease Wide Ban on Biotech CropsThe European Commission’s proposal expected on Tuesday will suggest allowing local and national governments to decide whether genetically modified crops should be grown.
>Europe’s New Approach to Biotech FoodAfter decades of pushing nations to surrender power, the European Union is about to throw in the towel on genetically modified foods.
>Europe Seeks New Approach to Biotech CropsAfter decades of pushing nations to surrender power, the European Union is about to throw in the towel on genetically modified foods.
>Europe Clears Import of New Biotech Corn VarietiesThe European Commission approved six genetically modified corn varieties for import to the bloc in another sign of its desire to speed up decision-making on the controversial technology.
>Exploring Algae as FuelDozens of bioengineering laboratories are trying to create superalgae that can be used to make diesel or jet fuel.
>Europeans Seek to Ease Wide Ban on Biotech CropsThe European Commission’s proposal expected on Tuesday will suggest allowing local and national governments to decide whether genetically modified crops should be grown.
>Europe’s New Approach to Biotech FoodAfter decades of pushing nations to surrender power, the European Union is about to throw in the towel on genetically modified foods.
>Europe Seeks New Approach to Biotech CropsAfter decades of pushing nations to surrender power, the European Union is about to throw in the towel on genetically modified foods.
New York Times- Pharmaceuticals
>Sanofi Is Expected to Bid $70 a Share for GenzymeA deal would bolster Sanofi’s drug pipeline and significantly increase its presence in biopharmaceuticals.
>Sanofi Said to Plan a Bid of $70 for GenzymeA deal would bolster Sanofi’s drug pipeline and significantly increase its presence in biopharmaceuticals.
>Hope Against Hepatitis CNew medicines being developed for Hepatitis C are making treatment more effective and less grueling on patients as infection rates reach roughly four million Americans and 170 million people worldwide; dozens of pharmaceutical companies are pursuing medications for virus, mainly because toll of disease, which now kills 12,000 Americans annually, is expected to rise in next decade; experts say majority of those infected will not benefit from treatment, as many are former or current IV-drug use...
>Novartis Plans Giveaway of New Children’s MedicineThe Swiss drug giant will give away up to 250,000 bottles of a liquid medicine to woo parents frustrated by the recall of liquid children’s Tylenol.
>Washington State Moves to Tighten Controls on Pain KillersRegulators in Washington State are attempting to stem what some see as the excessive use of prescribed narcotics.
>Sanofi Is Expected to Bid $70 a Share for GenzymeA deal would bolster Sanofi’s drug pipeline and significantly increase its presence in biopharmaceuticals.
>Sanofi Said to Plan a Bid of $70 for GenzymeA deal would bolster Sanofi’s drug pipeline and significantly increase its presence in biopharmaceuticals.
>Hope Against Hepatitis CNew medicines being developed for Hepatitis C are making treatment more effective and less grueling on patients as infection rates reach roughly four million Americans and 170 million people worldwide; dozens of pharmaceutical companies are pursuing medications for virus, mainly because toll of disease, which now kills 12,000 Americans annually, is expected to rise in next decade; experts say majority of those infected will not benefit from treatment, as many are former or current IV-drug use...
>Novartis Plans Giveaway of New Children’s MedicineThe Swiss drug giant will give away up to 250,000 bottles of a liquid medicine to woo parents frustrated by the recall of liquid children’s Tylenol.
>Washington State Moves to Tighten Controls on Pain KillersRegulators in Washington State are attempting to stem what some see as the excessive use of prescribed narcotics.
OnBioVC
>Curexo Technology Corp.: Series C $13.2MCurexo Technology (Korea) a commercial-stage medical device company focused on robotic surgical systems for joint replacement, closed a $13.2M Series C financing. Participants were not identified.
>Ensysce Biosciences, Inc.: Series A $1.5MEnsysce Biosciences (Houston, TX) a development-stage biopharma company focused on carbon nanotube complexes for chemotherapeutic transport, closed a $1.5M Series A financing. Participants include Texas Emerging Technology Fund.
>Green Biologics, Ltd.: Series B $6.1MGreen Biologics (United Kingdom) a development-stage biotechnology fermentation company focused on bio-butanol for biochemicals and biofuels, closed a $6.1M Series B financing. Participants include Capricorn Venture Partners, Morningside Ventures, Carbon Trust Investment Limited and Oxford Capital Partners.
>Zymeworks, Inc.: Series B $3.2MZymeworks (Canada) a development-stage bioinformatics company focused on in silico optimization of protein-based therapeutics, closed a $3.2M Series B financing. Participants include CTI Life Sciences Fund.
>Molecular Detection, Inc.: Series C $1.4MMolecular Detection (Wayne, PA) a commercial-stage molecular diagnostics company focused on MRSA detection, closed a $1.4M Series C financing, bringing the total round to $4.7M. Participants include MentorTech Ventures.
>Curexo Technology Corp.: Series C $13.2MCurexo Technology (Korea) a commercial-stage medical device company focused on robotic surgical systems for joint replacement, closed a $13.2M Series C financing. Participants were not identified.
>Ensysce Biosciences, Inc.: Series A $1.5MEnsysce Biosciences (Houston, TX) a development-stage biopharma company focused on carbon nanotube complexes for chemotherapeutic transport, closed a $1.5M Series A financing. Participants include Texas Emerging Technology Fund.
>Green Biologics, Ltd.: Series B $6.1MGreen Biologics (United Kingdom) a development-stage biotechnology fermentation company focused on bio-butanol for biochemicals and biofuels, closed a $6.1M Series B financing. Participants include Capricorn Venture Partners, Morningside Ventures, Carbon Trust Investment Limited and Oxford Capital Partners.
>Zymeworks, Inc.: Series B $3.2MZymeworks (Canada) a development-stage bioinformatics company focused on in silico optimization of protein-based therapeutics, closed a $3.2M Series B financing. Participants include CTI Life Sciences Fund.
>Molecular Detection, Inc.: Series C $1.4MMolecular Detection (Wayne, PA) a commercial-stage molecular diagnostics company focused on MRSA detection, closed a $1.4M Series C financing, bringing the total round to $4.7M. Participants include MentorTech Ventures.
Outsourcing-Pharma
>Demand for discovery services recovering, says DomainexDemand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.
>Biomarkers ?indispensible? in cancer drug development, says QuintilesCRO Quintiles says biomarkers give insight into cancer drug candidates? efficacy earlier in the development process, reducing trial costs and duration.
>Data, patients and payers key to ?New Health? success, says QuintilesQuintiles? Jay Norman tells Outsourcing-pharma that data sharing and patient and payer concerns will drive drug industry competition and clinical development decisions accord to new research.
>Safety and value driving Phase IV growth at CROs; EVPIncreased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.
>Potential for trials in Russia "enormous", says ClinStarRussia, the Ukraine and Belarus have emerged as destinations for clinical studies and now offer ?enormous? potential according to US-based CRO ClinStar.
>Demand for discovery services recovering, says DomainexDemand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.
>Biomarkers ?indispensible? in cancer drug development, says QuintilesCRO Quintiles says biomarkers give insight into cancer drug candidates? efficacy earlier in the development process, reducing trial costs and duration.
>Data, patients and payers key to ?New Health? success, says QuintilesQuintiles? Jay Norman tells Outsourcing-pharma that data sharing and patient and payer concerns will drive drug industry competition and clinical development decisions accord to new research.
>Safety and value driving Phase IV growth at CROs; EVPIncreased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.
>Potential for trials in Russia "enormous", says ClinStarRussia, the Ukraine and Belarus have emerged as destinations for clinical studies and now offer ?enormous? potential according to US-based CRO ClinStar.
Pharma News - Business Wire
>Teva Announces Agreement with Competition Bureau of Canada Regarding Proposed Merger with RatiopharmJERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that the Competition Bureau in Canada has reached an agreement with Teva Canada Limited and the Merckle Group, carrying on business as ratiopharm, stating that they will not challenge the transaction and the Companies are free to close without competition-related risk. Teva is pleased with the outcome which will allow us to fully realize the expected benefits of this merger in Canada. About Teva Tev...
>Gilead Closes Sale of $2.2 Billion of Convertible Senior NotesFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the closing of its sale of $1.1 billion aggregate principal amount of 1.00% convertible senior notes due 2014 and $1.1 billion aggregate principal amount of 1.625% convertible senior notes due 2016 to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the ?Securities Act?). The net proceeds from this offering were approximately $2.166 billion, after ...
>SENOMYX, INC. SECOND QUARTER 2010 EARNINGS CONFERENCE CALL SCHEDULED FOR AUGUST 5, 2010SAN DIEGO--(BUSINESS WIRE)--Senomyx (NASDAQ:SNMX) to provide corporate update and review 2Q10 results during a conference call on 8-5-10 at 11:00am EDT. Audio at IR tab on www.senomyx.com or call 888-679-8018 (passcode 42596600)
>Board of Directors of Genta Incorporated Announce Reverse Split of Company's Common StockBERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GETA) announced today that its Board of Directors has approved a one-for-one hundred reverse stock split of Genta?s common stock, and that the split will be effective with the open of trading on August 2, 2010. As of that date, the Company?s common stock will temporarily trade under the symbol GETAD.OB for 20 business days, at which time the symbol will revert to GETA.OB. At the Annual Meeting of Stockholders held on June 15,...
>QPharma, Inc. Launches qSpendTMMORRISTOWN, N.J.--(BUSINESS WIRE)--QPharma, Inc., the industry leader in FDA Regulatory and Compliance Solutions, announced today the official release of their aggregate spend solution, qSpendTM. This tool assists Pharmaceutical, Biotechnology, and Medical Device companies in complying with countless state and federal laws, regulations, and industry guidelines governing sales and marketing. qSpend is QPharma?s cost-efficient, aggregate spend solution for tracking, evaluating, and reporting sa...
>Teva Announces Agreement with Competition Bureau of Canada Regarding Proposed Merger with RatiopharmJERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that the Competition Bureau in Canada has reached an agreement with Teva Canada Limited and the Merckle Group, carrying on business as ratiopharm, stating that they will not challenge the transaction and the Companies are free to close without competition-related risk. Teva is pleased with the outcome which will allow us to fully realize the expected benefits of this merger in Canada. About Teva Tev...
>Gilead Closes Sale of $2.2 Billion of Convertible Senior NotesFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the closing of its sale of $1.1 billion aggregate principal amount of 1.00% convertible senior notes due 2014 and $1.1 billion aggregate principal amount of 1.625% convertible senior notes due 2016 to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the ?Securities Act?). The net proceeds from this offering were approximately $2.166 billion, after ...
>SENOMYX, INC. SECOND QUARTER 2010 EARNINGS CONFERENCE CALL SCHEDULED FOR AUGUST 5, 2010SAN DIEGO--(BUSINESS WIRE)--Senomyx (NASDAQ:SNMX) to provide corporate update and review 2Q10 results during a conference call on 8-5-10 at 11:00am EDT. Audio at IR tab on www.senomyx.com or call 888-679-8018 (passcode 42596600)
>Board of Directors of Genta Incorporated Announce Reverse Split of Company's Common StockBERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GETA) announced today that its Board of Directors has approved a one-for-one hundred reverse stock split of Genta?s common stock, and that the split will be effective with the open of trading on August 2, 2010. As of that date, the Company?s common stock will temporarily trade under the symbol GETAD.OB for 20 business days, at which time the symbol will revert to GETA.OB. At the Annual Meeting of Stockholders held on June 15,...
>QPharma, Inc. Launches qSpendTMMORRISTOWN, N.J.--(BUSINESS WIRE)--QPharma, Inc., the industry leader in FDA Regulatory and Compliance Solutions, announced today the official release of their aggregate spend solution, qSpendTM. This tool assists Pharmaceutical, Biotechnology, and Medical Device companies in complying with countless state and federal laws, regulations, and industry guidelines governing sales and marketing. qSpend is QPharma?s cost-efficient, aggregate spend solution for tracking, evaluating, and reporting sa...
Pharma News - PharmiWeb
>PharmiWeb Continues its ExpansionPharmiWeb Continues its Expansion Bracknell, July 30th 2010 - PharmiWeb Solutions, the Total Digital Marketing company for th...PharmiWeb Solutions
>SORIN GROUP Delivers Solid Results for the First Half Of 2010 And Improves the Guidance for the Full YearSORIN GROUP Delivers Solid Results for the First Half Of 2010 And Improves the Guidance for the Full YearResults of the Second ...SORIN GROUP
>Doctors.net.uk strengthens pharmaceutical team; new hires support strong business growthDoctors.net.uk strengthens pharmaceutical team; new hires support strong business growth Doctors.net.uk, the UK’s...Doctors.net.uk
>Chiltern Announces Financials for the Year Ended 31 March 2010Chiltern Announces Financials for the Year Ended 31 March 2010 CHILTERN ANNOUNCES ITS FINANCIAL RESULTS FOR THE YEAR ENDED 31...Chiltern
>Pharmacy OneSource Announces Free Webinar on Hospital-Acquired InfectionsPharmacy OneSource Announces Free Webinar on Hospital-Acquired Infections Assessing strategies to prevent healthcare-associat...Pharmacy OneSource
>PharmiWeb Continues its ExpansionPharmiWeb Continues its Expansion Bracknell, July 30th 2010 - PharmiWeb Solutions, the Total Digital Marketing company for th...PharmiWeb Solutions
>SORIN GROUP Delivers Solid Results for the First Half Of 2010 And Improves the Guidance for the Full YearSORIN GROUP Delivers Solid Results for the First Half Of 2010 And Improves the Guidance for the Full YearResults of the Second ...SORIN GROUP
>Doctors.net.uk strengthens pharmaceutical team; new hires support strong business growthDoctors.net.uk strengthens pharmaceutical team; new hires support strong business growth Doctors.net.uk, the UK’s...Doctors.net.uk
>Chiltern Announces Financials for the Year Ended 31 March 2010Chiltern Announces Financials for the Year Ended 31 March 2010 CHILTERN ANNOUNCES ITS FINANCIAL RESULTS FOR THE YEAR ENDED 31...Chiltern
>Pharmacy OneSource Announces Free Webinar on Hospital-Acquired InfectionsPharmacy OneSource Announces Free Webinar on Hospital-Acquired Infections Assessing strategies to prevent healthcare-associat...Pharmacy OneSource
Pharma News - PR Newswire
>Perrigo Confirms Filing for Generic Version of Gynazole-1® Cream and Announcement of Patent Infringement Lawsuit by KV PharmaALLEGAN, Mich., July 30 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for butoconazole nitrate vaginal cream, 2% and that is has notified KV Pharmaceutical Company,
>FDA Approves Vaccines for the 2010-2011 Influenza SeasonSILVER SPRING, Md., July 30 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that it has approved vaccines for the 2010-2011 influenza season in the United States. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20
>Mylan Announces Pricing of Add-On Offering of Senior NotesPITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes are being offered as addi
>Sanofi Pasteur Begins Shipping Influenza Vaccine in U.S. for 2010-2011 SeasonSWIFTWATER, Pa., July 30 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that shipping of the 2010-2011 formulation of its seasonal influenza vaccine Fluzone® Influenza Virus Vaccine is underway in the U.S. T
>GlaxoSmithKline Begins Distribution of Flu Vaccine to U.S. Customers for 2010-2011 Flu SeasonPHILADELPHIA, July 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval® [Influenza Virus Vaccine] allowing distribution in the U.S.
>Perrigo Confirms Filing for Generic Version of Gynazole-1® Cream and Announcement of Patent Infringement Lawsuit by KV PharmaALLEGAN, Mich., July 30 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for butoconazole nitrate vaginal cream, 2% and that is has notified KV Pharmaceutical Company,
>FDA Approves Vaccines for the 2010-2011 Influenza SeasonSILVER SPRING, Md., July 30 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that it has approved vaccines for the 2010-2011 influenza season in the United States. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20
>Mylan Announces Pricing of Add-On Offering of Senior NotesPITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes are being offered as addi
>Sanofi Pasteur Begins Shipping Influenza Vaccine in U.S. for 2010-2011 SeasonSWIFTWATER, Pa., July 30 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that shipping of the 2010-2011 formulation of its seasonal influenza vaccine Fluzone® Influenza Virus Vaccine is underway in the U.S. T
>GlaxoSmithKline Begins Distribution of Flu Vaccine to U.S. Customers for 2010-2011 Flu SeasonPHILADELPHIA, July 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval® [Influenza Virus Vaccine] allowing distribution in the U.S.
Pharmaceutical - Moreover
>Govt may use cash lying unclaimed in banks for welfareconsumer welfare fund, the NGO has also sought inclusion of the following excess charges * Amounts recovered from pharmaceutical companies by the National Pharmaceutical Pricing Authority having been overcharged from consumers. * Unclaimed deposits or
>Gas cuts choke off chemical exportsprice of $250 for each tonnes. Kafco exports fertiliser to Australia, Thailand, Vietnam, Pakistan and India. Earnings from pharmaceutical exports also shrank by around 10.3 percent in the last fiscal year. Industry executives blamed the global financial
>AIOCD Offers Private Label Medicinesin demand of pharmaceuticals from the society, and in view of the government giving importance to generic medicines, pharmaceutical dealers from all over the country had asked AIOCD to bring private label' generic to the market. As a result, the company
>Novartis India first quarter net marginally down at Rs 31.53 crorePharmaceutical firm Novartis India has declared its first quarter financial results for the fiscal year 2010-11. The company has informed that there has been a marginal decline in its net profit
>Novel Octreotide Dicarba-analogues with High Affinity and Different Selectivity for Somatostatin ReceptorsDepartment of Chemistry ?Ugo Schiff?, University of Firenze, Via della Lastruccia 5-13, I-50019, Sesto Fiorentino, Italy? Department of Pharmaceutical Chemistry and Toxicology, University of Napoli, Via Domenico Montesano 49, I-80131 Napoli, Italy
>Govt may use cash lying unclaimed in banks for welfareconsumer welfare fund, the NGO has also sought inclusion of the following excess charges * Amounts recovered from pharmaceutical companies by the National Pharmaceutical Pricing Authority having been overcharged from consumers. * Unclaimed deposits or
>Gas cuts choke off chemical exportsprice of $250 for each tonnes. Kafco exports fertiliser to Australia, Thailand, Vietnam, Pakistan and India. Earnings from pharmaceutical exports also shrank by around 10.3 percent in the last fiscal year. Industry executives blamed the global financial
>AIOCD Offers Private Label Medicinesin demand of pharmaceuticals from the society, and in view of the government giving importance to generic medicines, pharmaceutical dealers from all over the country had asked AIOCD to bring private label' generic to the market. As a result, the company
>Novartis India first quarter net marginally down at Rs 31.53 crorePharmaceutical firm Novartis India has declared its first quarter financial results for the fiscal year 2010-11. The company has informed that there has been a marginal decline in its net profit
>Novel Octreotide Dicarba-analogues with High Affinity and Different Selectivity for Somatostatin ReceptorsDepartment of Chemistry ?Ugo Schiff?, University of Firenze, Via della Lastruccia 5-13, I-50019, Sesto Fiorentino, Italy? Department of Pharmaceutical Chemistry and Toxicology, University of Napoli, Via Domenico Montesano 49, I-80131 Napoli, Italy
PR Leap - Biotech
>Executive Impact Group Provides Startup Solutions to VC funded $40M Calithera Biosciences Executive Impact Group providing expertise startup solutions, operations and human capital management services to Calithera Biosciences
>Vivante GMP Solutions Announces Expansion of Technical Staff Vivante GMP Solutions, Inc. ("Vivante"; www.vivante-gmp.com) today announced that it has increased its technical staff in order to assist the Company in its continued growth as a leader in the virus-based biologics contract manufacturing space. Additional staff has been added in the areas of Manufacturing, Quality Assurance, and Quality Control.
>Vivante GMP Solutions Announces Successful Completion of GMP Manufacture, Lot Release Campaign Vivante GMP Solutions, Inc. ("Vivante"; www.vivante-gmp.com) today announced that it has successfully completed the GMP manufacture and lot release analysis for a privately-held US biotech company of its virus vector-based gene therapy product for use in Phase I clinical trials.
>SourceSolution Announces the Implementation of the PlanIt Partner Portal for Vivante GMP Solutions SourceSolution, a leader in Supplier Relationship Management (SRM) software for the biotechnology and pharmaceutical industries, announced that it has implemented its partner portal solution, PlanIt, for Vivante GMP Solutions. PlanIt is a Software-as-a-Service (SaaS) application that streamlines project communications with internal and external team members without installing and maintaining new software.
>Vivante GMP Solutions Announces Successful Completion of GMP Fill/Finish, Lot Release Campaign for Etubics Corporation Vivante GMP Solutions, Inc. ("Vivante"; www.vivante-gmp.com) today announced that it has successfully completed the fill/finish and lot release testing for Etubics Corporation's ("Etubics"; www.etubics.com) ETBX-011 adenovirus vector-based gene therapy product for Phase I/II clinical trials.
>Executive Impact Group Provides Startup Solutions to VC funded $40M Calithera Biosciences Executive Impact Group providing expertise startup solutions, operations and human capital management services to Calithera Biosciences
>Vivante GMP Solutions Announces Expansion of Technical Staff Vivante GMP Solutions, Inc. ("Vivante"; www.vivante-gmp.com) today announced that it has increased its technical staff in order to assist the Company in its continued growth as a leader in the virus-based biologics contract manufacturing space. Additional staff has been added in the areas of Manufacturing, Quality Assurance, and Quality Control.
>Vivante GMP Solutions Announces Successful Completion of GMP Manufacture, Lot Release Campaign Vivante GMP Solutions, Inc. ("Vivante"; www.vivante-gmp.com) today announced that it has successfully completed the GMP manufacture and lot release analysis for a privately-held US biotech company of its virus vector-based gene therapy product for use in Phase I clinical trials.
>SourceSolution Announces the Implementation of the PlanIt Partner Portal for Vivante GMP Solutions SourceSolution, a leader in Supplier Relationship Management (SRM) software for the biotechnology and pharmaceutical industries, announced that it has implemented its partner portal solution, PlanIt, for Vivante GMP Solutions. PlanIt is a Software-as-a-Service (SaaS) application that streamlines project communications with internal and external team members without installing and maintaining new software.
>Vivante GMP Solutions Announces Successful Completion of GMP Fill/Finish, Lot Release Campaign for Etubics Corporation Vivante GMP Solutions, Inc. ("Vivante"; www.vivante-gmp.com) today announced that it has successfully completed the fill/finish and lot release testing for Etubics Corporation's ("Etubics"; www.etubics.com) ETBX-011 adenovirus vector-based gene therapy product for Phase I/II clinical trials.
PRWeb - Biotechnology
>National Patient Antibody Registry, LLC Announces On-line Demo NPAR can now be viewed through a web-based video that highlights NPAR?s features and benefits. DJ Molny, Lead Architect states ?The NPAR system is designed to be intuitive and user-friendly. The video...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4312374.htm
>Adventus Group Establishes Joint Venture for European Expansion with... Adventus Group, a global remediation technology enterprise, announces that it has signed an agreement for establishment of a joint venture (JV) with S&B Industrial Minerals. The agreement was signed...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4321014.htm
>Quantum Resonance Calibration Standards Replacing Old Fashioned Liquid... Spectrophotometers and the spectroscopy industry have evolved over the course of time and as they evolved so has the technology for calibrating the equipment. Fireflysci's revolutionary calibration...(PRWeb July 30, 2010)Read the full story at http://www.prweb.com/releases/fireflysci/calibration/prweb4328884.htm
>Scienceware® Clear View Glove Boxes Designed for Diverse Market Scienceware Clear View Glove Boxes from Bel-Art Products provide an isolated work environment for processing samples or handling sensitive materials. Made of clear polycarbonate they are durable,...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4322624.htm
>LS9, Inc. Makes Major Scientific Breakthrough in Converting Sugar to... Production Capabilities Successfully Demonstrated at Pilot Scale(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4324034.htm
>National Patient Antibody Registry, LLC Announces On-line Demo NPAR can now be viewed through a web-based video that highlights NPAR?s features and benefits. DJ Molny, Lead Architect states ?The NPAR system is designed to be intuitive and user-friendly. The video...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4312374.htm
>Adventus Group Establishes Joint Venture for European Expansion with... Adventus Group, a global remediation technology enterprise, announces that it has signed an agreement for establishment of a joint venture (JV) with S&B Industrial Minerals. The agreement was signed...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4321014.htm
>Quantum Resonance Calibration Standards Replacing Old Fashioned Liquid... Spectrophotometers and the spectroscopy industry have evolved over the course of time and as they evolved so has the technology for calibrating the equipment. Fireflysci's revolutionary calibration...(PRWeb July 30, 2010)Read the full story at http://www.prweb.com/releases/fireflysci/calibration/prweb4328884.htm
>Scienceware® Clear View Glove Boxes Designed for Diverse Market Scienceware Clear View Glove Boxes from Bel-Art Products provide an isolated work environment for processing samples or handling sensitive materials. Made of clear polycarbonate they are durable,...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4322624.htm
>LS9, Inc. Makes Major Scientific Breakthrough in Converting Sugar to... Production Capabilities Successfully Demonstrated at Pilot Scale(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4324034.htm
PRWeb - Pharmaceuticals
>E-BEAM Facilities Quality Management Systems ISO Certified ? Including... E-BEAM Services, Inc. validates its Quality Management System for Medical Devices by attaining ISO 13485 certification and renewing ISO 9001 accreditation at three of its ebeam processing facilities,...(PRWeb July 30, 2010)Read the full story at http://www.prweb.com/releases/ISO13485/sterilization/prweb4328514.htm
>Global Health Progress Highlights ViiV Healthcare's Announcement of... Initiatives will improve access to HIV medicines for people living in the least developed countries(PRWeb July 30, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4323814.htm
>Global Health Progress Epitomizes Clinton, Gates' Call for "Efficiency... GHP?s highlights importance of collaborative partnerships and securing resources, such as access to drugs(PRWeb July 30, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4323874.htm
>Christiane Wells, MSW, publishes second book: ?Magical Shrinking:... "Magical Shrinking'" is an autobiographical account of potential, despair, mental illness, and addiction. The book includes a creative coping mechanism developed by Wells as a child in which she's...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4317774.htm
>Senator Dan Inouye and Governor Ed Rendell to be Recognized at the... Inaugural National Convenient Care Clinic Week designed to highlight the importance of convenient care clinics and practioners in offering affordable and convenient health care. During the event,...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4321854.htm
>E-BEAM Facilities Quality Management Systems ISO Certified ? Including... E-BEAM Services, Inc. validates its Quality Management System for Medical Devices by attaining ISO 13485 certification and renewing ISO 9001 accreditation at three of its ebeam processing facilities,...(PRWeb July 30, 2010)Read the full story at http://www.prweb.com/releases/ISO13485/sterilization/prweb4328514.htm
>Global Health Progress Highlights ViiV Healthcare's Announcement of... Initiatives will improve access to HIV medicines for people living in the least developed countries(PRWeb July 30, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4323814.htm
>Global Health Progress Epitomizes Clinton, Gates' Call for "Efficiency... GHP?s highlights importance of collaborative partnerships and securing resources, such as access to drugs(PRWeb July 30, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4323874.htm
>Christiane Wells, MSW, publishes second book: ?Magical Shrinking:... "Magical Shrinking'" is an autobiographical account of potential, despair, mental illness, and addiction. The book includes a creative coping mechanism developed by Wells as a child in which she's...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4317774.htm
>Senator Dan Inouye and Governor Ed Rendell to be Recognized at the... Inaugural National Convenient Care Clinic Week designed to highlight the importance of convenient care clinics and practioners in offering affordable and convenient health care. During the event,...(PRWeb July 29, 2010)Read the full story at http://www.prweb.com/releases/2010/07/prweb4321854.htm
Scientific American
>Weather or Not?: Last Winter's Record Snow Driven by Short-Term Meteorologic Patterns, Not Long-Term Climate ChangeJust six months ago residents of the eastern U.S. were shoveling themselves out of the snowiest winter ever--weather that prompted mockery of global warming among some people . Now, scientists have a new explanation for why such anomalous snowstorms can coexist with global warming: The storms were kicked up by the convergence of two natural, large-scale weather patterns.In order to better understand possible triggers of last year's media-dubbed " snowmaggedon ," a team of scientists fro...
>Safety Concerns Delay Approval of the First U.S. Nuclear Reactor in DecadesA new era for nuclear power is taking shape as third-generation reactors, designed to be simpler and safer, inch through the U.S. Nuclear Regulatory Commission's (NRC) design certification process. Much of nuclear's revival hinges on the ability of new reactors to outshine those of yore in terms of safety, economics, construction time and life span. [More] Nuclear Regulatory Commission - Nuclear power - Nuclear reactor technology - Nuclear - Energy
>Genes from Ebola Virus Family Found in Human GenomeViruses do not make good fossils. But advances in genomic technology have allowed scientists to peer into the genetic material of viruses and their hosts to search for clues about their shared evolutionary history. [More] Ebola - Genome - Gene - Virus - Biology
>Dopamine Determines Impulsive Behavior Binge-shoppers and serial daters might perpetually be living at the whim of their latest impulse, and now research is getting to the biological basis of their seemingly random behavior. [More] Health - Psychology - Social Sciences - Addiction - Mental health
>Safety Concerns Have Delayed Approval of First U.S. Nuclear Reactor in DecadesA new era for nuclear power is taking shape as third-generation reactors, designed to be simpler and safer, inch through the Nuclear Regulatory Commission's (NRC) design certification process. Much of nuclear's revival hinges on the ability of new reactors to outshine those of yore in terms of safety, economics, construction time and life span. [More] Nuclear Regulatory Commission - Nuclear power - Nuclear reactor technology - Nuclear - Energy
>Weather or Not?: Last Winter's Record Snow Driven by Short-Term Meteorologic Patterns, Not Long-Term Climate ChangeJust six months ago residents of the eastern U.S. were shoveling themselves out of the snowiest winter ever--weather that prompted mockery of global warming among some people . Now, scientists have a new explanation for why such anomalous snowstorms can coexist with global warming: The storms were kicked up by the convergence of two natural, large-scale weather patterns.In order to better understand possible triggers of last year's media-dubbed " snowmaggedon ," a team of scientists fro...
>Safety Concerns Delay Approval of the First U.S. Nuclear Reactor in DecadesA new era for nuclear power is taking shape as third-generation reactors, designed to be simpler and safer, inch through the U.S. Nuclear Regulatory Commission's (NRC) design certification process. Much of nuclear's revival hinges on the ability of new reactors to outshine those of yore in terms of safety, economics, construction time and life span. [More] Nuclear Regulatory Commission - Nuclear power - Nuclear reactor technology - Nuclear - Energy
>Genes from Ebola Virus Family Found in Human GenomeViruses do not make good fossils. But advances in genomic technology have allowed scientists to peer into the genetic material of viruses and their hosts to search for clues about their shared evolutionary history. [More] Ebola - Genome - Gene - Virus - Biology
>Dopamine Determines Impulsive Behavior Binge-shoppers and serial daters might perpetually be living at the whim of their latest impulse, and now research is getting to the biological basis of their seemingly random behavior. [More] Health - Psychology - Social Sciences - Addiction - Mental health
>Safety Concerns Have Delayed Approval of First U.S. Nuclear Reactor in DecadesA new era for nuclear power is taking shape as third-generation reactors, designed to be simpler and safer, inch through the Nuclear Regulatory Commission's (NRC) design certification process. Much of nuclear's revival hinges on the ability of new reactors to outshine those of yore in terms of safety, economics, construction time and life span. [More] Nuclear Regulatory Commission - Nuclear power - Nuclear reactor technology - Nuclear - Energy
Xconomy Life Sciences
>Hutch Names Larry Corey as New President, To Build on Hartwell's Growth LegacyThe Fred Hutchinson Cancer Research Center, one of the world’s leading centers for biomedical research and innovation, has found its new leader after a year of searching. Larry Corey, the international HIV vaccine expert, has been named to replace the retiring Nobel laureate Lee Hartwell, 70, in the top job at the Seattle-based nonprofit research [...]
>Charles River Ends $1.6B WuXi BuyoutCharles River Laboratories International (NYSE:CRL), a provider of lab mice and drug research services, said yesterday that it nixed its plans to acquire the China-based contract research juggernaut WuXi PharmaTech (Cayman) (NYSE:WX) for $1.6 billion due to lack of support for the deal among its shareholders. Wilmington, MA-based Charles River is paying WuXi a $30 [...]
>Connect Adopts New Measures to Boost the Innovation EconomyConnect, the San Diego nonprofit group for technology and entrepreneurship, said its board has approved a series of initiatives intended to stimulate the long-term formation of technology startups. The initiatives, which will be supervised by Connect CEO Duane Roth, are supposed to attract more early stage investment capital, and influence innovation policies set by the [...]
>Gates Foundation's Tachi Yamada: Biotechies and VCs are Missing Out on Global HealthTachi Yamada was a big name in Big Pharma before he took the top global health job at the world’s richest charitable organization, the Bill & Melinda Gates Foundation. But no single organization—not even a multi-national, multi-billion dollar R&D shop at GlaxoSmithKline, or the Gates Foundation—can conquer leading killers like HIV, tuberculosis, diarrheal diseases, and [...]
>LS9 Reveals Key Biofuel Genes, Onyx Drug Passes Big Trial, Solazyme Seeks First-Mover Edge, & More Bay Area Life Sciences NewsThis week we had reports from a couple of the leading biofuel companies in the Bay Area, along with a noteworthy advance from a cancer drug developer. —LS9, the South San Francisco-based biofuel company, reported in this week’s edition of Science magazine how it discovered genes in cyanobacteria that it hopes will pave the way to [...]
>Hutch Names Larry Corey as New President, To Build on Hartwell's Growth LegacyThe Fred Hutchinson Cancer Research Center, one of the world’s leading centers for biomedical research and innovation, has found its new leader after a year of searching. Larry Corey, the international HIV vaccine expert, has been named to replace the retiring Nobel laureate Lee Hartwell, 70, in the top job at the Seattle-based nonprofit research [...]
>Charles River Ends $1.6B WuXi BuyoutCharles River Laboratories International (NYSE:CRL), a provider of lab mice and drug research services, said yesterday that it nixed its plans to acquire the China-based contract research juggernaut WuXi PharmaTech (Cayman) (NYSE:WX) for $1.6 billion due to lack of support for the deal among its shareholders. Wilmington, MA-based Charles River is paying WuXi a $30 [...]
>Connect Adopts New Measures to Boost the Innovation EconomyConnect, the San Diego nonprofit group for technology and entrepreneurship, said its board has approved a series of initiatives intended to stimulate the long-term formation of technology startups. The initiatives, which will be supervised by Connect CEO Duane Roth, are supposed to attract more early stage investment capital, and influence innovation policies set by the [...]
>Gates Foundation's Tachi Yamada: Biotechies and VCs are Missing Out on Global HealthTachi Yamada was a big name in Big Pharma before he took the top global health job at the world’s richest charitable organization, the Bill & Melinda Gates Foundation. But no single organization—not even a multi-national, multi-billion dollar R&D shop at GlaxoSmithKline, or the Gates Foundation—can conquer leading killers like HIV, tuberculosis, diarrheal diseases, and [...]
>LS9 Reveals Key Biofuel Genes, Onyx Drug Passes Big Trial, Solazyme Seeks First-Mover Edge, & More Bay Area Life Sciences NewsThis week we had reports from a couple of the leading biofuel companies in the Bay Area, along with a noteworthy advance from a cancer drug developer. —LS9, the South San Francisco-based biofuel company, reported in this week’s edition of Science magazine how it discovered genes in cyanobacteria that it hopes will pave the way to [...]
Yahoo Biotech News
>EU clears six types of GM maize for animal feed (AFP) AFP - European regulators authorised on Wednesday the import of six types of genetically-modified maize for use in animal feed after governments were deadlocked over whether to ban or approve them.
>Genes Influence Your Response to Others' Drinking Habits (LiveScience.com) LiveScience.com - Your genes may determine how likely you are to imitate the drinking habits of others, new research suggests.
>Hospital denies suspected killer got new liver (Reuters) Reuters - The widely reported liver transplant at the New York-Presbyterian Hospital to alleged killer Johnny Concepcion never took place, a spokesperson told Reuters Health on Tuesday. On Monday, the New York Post said Concepcion, 43, who allegedly stabbed his wife to death earlier this month, had gotten a liver transplant at the hospital after eating rat poison in a suicide attempt. The story quickly took off, making headlines such as msnbc.com's "Many outraged as accused murderer gets li...
>Benefit confirmed in "bubble boy" treatment (Reuters) Reuters - A 10-year study of nine boys born without the ability to ward off germs has found that gene therapy is an effective long-term treatment, but it carries a price: four of them developed leukemia.
>Gene Therapy Shows Promise With 'Bubble Boy' Disease (HealthDay) HealthDay - WEDNESDAY, July 21 (HealthDay News) -- Eight of nine male infants born with so-called "Bubble Boy" disease were still alive and well nine years after they underwent gene therapy, French researchers report.
>EU clears six types of GM maize for animal feed (AFP) AFP - European regulators authorised on Wednesday the import of six types of genetically-modified maize for use in animal feed after governments were deadlocked over whether to ban or approve them.
>Genes Influence Your Response to Others' Drinking Habits (LiveScience.com) LiveScience.com - Your genes may determine how likely you are to imitate the drinking habits of others, new research suggests.
>Hospital denies suspected killer got new liver (Reuters) Reuters - The widely reported liver transplant at the New York-Presbyterian Hospital to alleged killer Johnny Concepcion never took place, a spokesperson told Reuters Health on Tuesday. On Monday, the New York Post said Concepcion, 43, who allegedly stabbed his wife to death earlier this month, had gotten a liver transplant at the hospital after eating rat poison in a suicide attempt. The story quickly took off, making headlines such as msnbc.com's "Many outraged as accused murderer gets li...
>Benefit confirmed in "bubble boy" treatment (Reuters) Reuters - A 10-year study of nine boys born without the ability to ward off germs has found that gene therapy is an effective long-term treatment, but it carries a price: four of them developed leukemia.
>Gene Therapy Shows Promise With 'Bubble Boy' Disease (HealthDay) HealthDay - WEDNESDAY, July 21 (HealthDay News) -- Eight of nine male infants born with so-called "Bubble Boy" disease were still alive and well nine years after they underwent gene therapy, French researchers report.